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Summary 
 
The phenomenon of peptide and protein aggregation is of great biochemical importance. Not 
only is it a key feature of numerous neurodegenerative diseases such as Alzheimer's, 
Parkinson's or Huntington's disease, but it also plays a significant role in the manufacturing and 
processing of therapeutic peptides. In the process of producing pharmaceutical peptides, 
molecules are exposed to a wide variety of conditions, some of which enhance aggregation, 
such as high peptide concentrations. In addition, the long-term physical stability of therapeutic 
peptides is essential for storage and use of these drugs, and also influences their half-lives in 
vivo. Therefore, aggregation of peptide-based therapeutics remains a great challenge for the 
pharmaceutical industry. 
Aggregation is typically defined as a process involving the non-covalent association of 
polypeptide chains, however, in some cases aggregates can also be linked covalently. The 
process of aggregation proceeds via a multi-step mechanism: First, the monomeric peptide self-
associates to oligomeric structures, and these can form nucleating species which then further 
elongate to form amyloid fibrils. When a peptide aggregates, it leads not only to the loss of its 
biological activity but it can also give rise to other critical problems, e.g. toxicity and 
immunogenicity, associated with the formation of intermediate oligomeric species. 
This work is focused on the C-terminal amidated analogue of the commonly used peptide 
therapeutic, glucagon-like peptide 1 (GLP-1). This peptide is responsible for many regulatory 
mechanisms affecting the level of glucose in the bloodstream. Unfortunately, it was shown that 
GLP-1 has a great propensity to aggregate over a wide pH range that inhibits its function. The 
studies presented here establish that C-terminal amidation of this peptide hormone significantly 
slows its fibril formation at neutral and basic pH. It was found that during the significantly 
prolonged lag times, small stable soluble peptide oligomers start to form. These oligomers, 
which were characterised using a number of different biophysical techniques, may be off-
pathway species of amyloid fibril formation or products of partial peptide degradation. The 
aggregation kinetics were shown to differ below and above pH 8. However, it was demonstrated 
that oligomers formed during the process have similar structural characteristics. While amyloid 
fibrils have a characteristic cross β-sheet structure, the structure of small oligomers formed 
mainly during the lag and elongation and growth phases is highly disordered. Surprisingly, 
these small oligomers show a great stability. The exact role of these small, soluble disordered 
aggregates in fibrillation processes requires further investigation. 
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These results contribute to the understanding of a complex pathway of aggregation and 
misfolding processes by providing size and structural characterization of oligomeric species 
formed during the lag, elongation and growth phases.  
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ACN   acetonitrile 
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Chapter 1 
Introduction 
 
Aggregation is one of the most common forms of peptide and protein degradation. Extensive 
research has been undertaken on peptide and protein aggregation associated with numerous 
neurodegenerative diseases including Alzheimer’s, Parkinson’s and Huntington’s disease.1–5 
Another field where the stability and aggregation of peptides and proteins plays a key role is in 
the manufacturing and processing of therapeutic peptide drugs. During drug processing, 
peptides are exposed to a wide range of conditions that can enhance their propensity to 
aggregate. This includes high peptide concentrations, extreme pH values, high temperatures 
etc. Moreover, the long-term stability of peptides is essential for drug storage (shelf life) and it 
can also influence the drug’s half-life in vivo.6 
The term aggregation refers to many different processes during which peptide or protein 
monomers self-assemble into larger species. These processes can be either reversible or 
irreversible. Having complex structural landscapes, peptides and proteins may transform into a 
wide range of species, such as various insoluble aggregates, amyloid fibrils or small soluble 
oligomers.7,8 The nature of the aggregates formed can differ greatly and depends critically on 
many different factors. Aggregates can be amorphous or highly structured, and may consist of 
different numbers of monomer units, starting with dimers all the way to amyloid fibrils that 
consist of many hundreds, if not thousands, of monomer units. 
In this Thesis, the aggregation properties of a polypeptide hormone glucagon-like peptide 1 
(GLP-1) and its C-terminal amidated analogue (GLP-1-Am) were investigated. This peptide 
hormone is involved in many regulatory mechanisms affecting the blood glucose level in 
humans. It is able to reduce hyperglycemia in type 2 diabetic patients and therefore it is used 
for type 2 diabetes mellitus treatment.9–11 Unfortunately, GLP-1 aggregates into amyloid fibrils 
over a wide range of pH.12 However, C-terminal amidation of GLP-1 was recently shown to 
significantly slow down the fibrillation at neutral and basic pH.13 There are already a number 
of C-terminally modified GLP-1 analogues on the market. For example, the C-terminus has 
been used as a linkage site in commercially available GLP-1 active analogues that are fused 
with an antibody fragment (dulaglutide — Trulicity™).14 The main focus of this Thesis is an 
investigation of the aggregation behaviour of GLP-1-Am at neutral (Chapter 3) and basic 
(Chapter 4) pH values. 
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1.1 Therapeutic peptides  
Peptide therapeutics history goes back to the 1920s, when insulin therapy was developed. Since 
then, peptide-based drugs have played an important role in medicinal practice. Many peptides 
in the human body serve as hormones having a signalling role in physiological functions. Some 
of the peptide drugs are used in replacement therapies, where a shortage of a naturally secreted 
hormone is compensated for.10 At the beginning of the peptide therapeutics era, peptide drugs 
were isolated from natural sources, e.g. insulin or the adrenocorticotropic hormone. Nowadays, 
peptide drugs are either produced using recombinant DNA technology or by solid-phase peptide 
synthesis.9 Over seven thousand naturally occurring peptides have already been characterized, 
many of which play an essential role in human physiology. More than 80 approved peptide 
drugs are currently on the market and hundreds of others are currently in the process of 
development and in clinical trials or preclinical phases.11 Peptide drug development focuses 
mainly on metabolic and cardiovascular diseases, and oncology. Currently, the majority of 
peptide therapeutics are given in the form of injections, however, alternative administration 
routes are under extensive development, for instance, a transbuccal delivery system that uses 
insulin-passivated gold glyconanoparticles15 or oral delivery where peptides are directly 
expressed in the gastrointestinal tract by engineered bacterial strains.16 
Since 2005, the market of injectable GLP-1 agonists as a treatment for type 2 diabetes mellitus 
has continuously grown. Nowadays, GLP-1 agonists belong among the peptide drugs with the 
greatest financial turnover. In 2017, 47 peptide drugs that target the GLP-1 receptor entered 
clinical testing, five of which have already been approved.10 
1.1.1 Peptide therapeutics: stability 
The peptide therapeutics industry faces many challenges due to limitations in peptide drug 
stability. Among these, poor chemical and physical stability, and short plasma half-life are 
generally the most problematic. Short plasma half-lives are usually due to the natural presence 
of various peptidases that regulate hormone levels in the plasma to maintain homeostasis. These 
regulatory mechanisms are often inconvenient for the use of therapeutic peptide drugs.  
In terms of chemical and physical stability, the aggregation of peptides is one of the most 
common problems. Peptide aggregates can be both non-covalent assemblies or covalently 
linked peptide chains depending on the chemical and physical stability of the specific peptide. 
When a peptide drug aggregates, it leads to a loss of its biological activity and other critical 
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problems, e.g. potential toxicity and immunogenicity of aggregated species. The mechanism(s) 
of peptide aggregation are described in more detail in Section 1.2.4. 
Peptide therapeutics are also prone to chemical degradation. There are many types of chemical 
degradation, such as isomerisation, deamidation17, racemisation, β-elimination, oxidation,18,19 
hydrolysis, formation or breakage of disulphide bonds, succinimidation20 or the Maillard 
reaction. These processes often change not only the chemical properties but also the physical 
properties of the peptide (e.g. hydrophobicity, net charge, secondary and/or tertiary structure) 
and therefore can significantly alter the peptide’s behaviour including an enhancement of its 
aggregation propensity.  
To overcome the obstacles associated with the intrinsic instability of peptide drugs, various 
synthetic strategies have been developed. These include direct modification of the peptide 
backbone, incorporation of non-natural amino acids, amino-acid side chain modification or 
conjugation to different moieties (e.g. lipidation, glycosylation or antibody fragment 
conjunction21) that improve solubility, administration or stability of the peptide. For instance, a 
peptide can be protected against enzymatic cleavage by the inclusion of lactam bridges, by 
cyclisation, or by stapling of the peptide sequence.22,23 Examples of peptide modifications used 
to improve stability and half-lives include peptide acylation, amidation or lipidation 
(e.g. liraglutide — a lipidated form of GLP-1,24 and insulin detemir — a lipidated form of 
insulin25). 
For some peptides, it has been shown that such modifications often suppress fibrillation but 
increase the rate of oligomer formation.6,26 Lipidated analogues of GLP-1 were shown to form 
oligomers of various sizes depending on the pH. 26,27 Similar effects have been observed after 
phosphorylation, citrullination or nitration of the Aβ peptide, where fibrillation processes were 
suppressed, but the formation of oligomers increased.4,28–31 For α-synuclein, whose aggregation 
is associated with Parkinson’s disease, the same trends were observed as well.32,33  
1.1.2 Factors affecting the stability of peptide therapeutics 
The effect of peptide sequence 
The propensity towards chemical or physical degradation is to a large extent determined by the 
amino-acid sequence of the peptide or protein. Some amino-acid residues are more prone to 
chemical degradation such as oxidation (Met, Trp, Tyr, His, Phe), hydrolysis (Trp, Asp), 
deamidation (Gln, Asn) or disulphide bridge formation (Cys).6 The propensity to self-assemble 
is, in part, also governed by the overall intrinsic properties of the amino-acid residues. This has 
been subject of extensive studies, and a range of software packages for the prediction of the 
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aggregation-prone regions (APR) in peptides and proteins have been developed (Section 
1.3.3).34–39 
The effect of pH and net charge  
The pH and therefore the net charge of the peptide determine the electrostatic interactions 
between the peptide monomers, which can influence their self-assembly. A higher net charge 
is generally associated with slower aggregation since a greater electrostatic repulsion needs to 
be overcome for oligomers and larger aggregates to form. Usually, peptides and proteins show 
the greatest propensity to aggregate around their pI where their solubility is the lowest.40–42 
However, there are exceptions to this rule, e.g. GLP-1 and its amidated analogue show the 
slowest aggregation (i.e. the lowest fibrillation rate) around their pI values.13 Some other 
peptides and proteins that can form amyloid fibrils still aggregate at their pI, but instead of 
highly regular fibrillary structures they form monodisperse and quasi-amorphous aggregates.43 
The effect of buffers and ionic strength 
Even though the main use of buffers is to modulate the pH, some buffers have a direct effect 
on the stability of peptides and proteins. The increase in stability in one buffer relative to a 
different one is usually explained by direct binding of the buffer molecules to the peptide or 
protein.44 It was reported that the phosphate buffer can increase the stability of the native state 
of some proteins, thereby reducing aggregation propensity.45,46 Several times, stabilisation has 
been observed with nitrogen-based buffers. For example, increased stability of antibodies has 
been reported in MES and histidine buffers.47,48 Similarly, histidine was shown to stabilise 
interferon-tau49 and recombinant human erythropoietin.50 In the case of interferon-tau, Tris 
buffer was also found to be an effective stabilising agent.49 In addition, citrate buffer has been 
shown to result in an increase in stability of antitrypsin51 and of human interleukin-1 receptor 
antagonist.52 
Various studies have shown that the ionic strength of the buffer can affect both the kinetics of 
aggregation and the structure of the resulting aggregates.53–56 For example, hen egg white 
lysozyme was reported to form rigid fibrils at low salt concentrations, but oligomers and curvi-
linear fibrils at higher salt concentrations. At pH 2 and 52 °C, a kinetic phase diagram was 
constructed for the fibril-to-oligomer transition as a function of protein concentration and ionic 
strength.55,56 
The stability of peptides can also be significantly affected by the nature of ions in solution and 
it usually follows the Hofmeister series. This series, originally proposed in 1888, is a qualitative 
ordering of ions based on their ability to salt-out proteins from aqueous solutions.57 Later, it 
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was discovered that many processes including enzymatic activity and protein folding also 
follow the same ordering.54,58 A large effect of ions on the aggregation propensity of numerous 
peptides and proteins has been shown, e.g., for Aβ,59 islet amyloid polypeptide53 and the mouse 
prion protein.60 
The effect of temperature and agitation  
Temperature and agitation play an important role in the physical stability of numerous peptides 
and proteins. Raising the temperature induces aggregation in many peptide or protein systems. 
However, aggregation kinetics often show non-Arrhenius behaviour over the temperature 
ranges studied.61 This makes it challenging to extrapolate aggregation kinetic data measured at 
higher temperatures to lower temperatures. 
Various agitation methods are routinely used in peptide and protein aggregation studies.62 
Agitation and the effect of shear forces on peptides and proteins are of practical interest, as 
many peptide pharmaceuticals, e.g. insulin, are subject to shear during the syringe pump 
delivery as well as during processing. Shear forces alone are unlikely to cause structural 
changes (protein denaturation) to a sufficient extent to initiate aggregation, however, they 
increase interfacial interactions (particularly at liquid/air interface) that can lead to protein 
interactions and self-assembly.63 Shear speeds up nucleation rates and protofibril formation but 
can, to some extent, limit the formation of mature fibrils, probably due to fibril fragmentation 
as has been shown for Aβ peptide.64 Nevertheless, in some cases, breakage of fibrils may further 
speed up the aggregation process since fibril fragments may act as nucleation seeds.8,65,66 
Different methods of agitation (shaking, stirring etc.) are common sources of inconsistencies in 
aggregation kinetic data obtained by different research groups and the lack of standardized 
aggregation protocols limits the comparison of kinetic data.62 
1.2 Peptide and protein aggregation 
In general, the amino-acid sequence of peptides and proteins with biological functions has 
coevolved with their physiological environments to maintain peptides and protein in their 
soluble states. However, under certain conditions, it is possible for many peptides and proteins 
to convert into non-functional and potentially damaging aggregates.7,67 The aggregation process 
starts with the formation of small clusters of monomers (oligomers). These clusters are usually 
rather unstable with only relatively weak inter-molecular interactions. However, these clusters 
can undergo internal reorganization to form more stable species.55,68 Sometimes, specific 
oligomers can act as nucleation species that, once formed, can further rapidly elongate to form 
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fibrils, which can coalesce to create large insoluble plaques such as those seen in some 
neurodegenerative diseases. 
1.2.1 Amyloid fibril formation 
Since amyloid fibrils are associated with a number of pathological conditions, including 
neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease, they are perhaps the 
most studied form of protein aggregates. However, amyloid fibrils are not only a pathological 
phenomenon; functional amyloid structures exist in microorganisms and animals.69–72 Also, 
many denatured proteins, not associated with any disease state, have also been shown to form 
amyloid fibrils.73 These fibrils can have an even higher stability than the native state of the 
protein. This is true especially for shorter peptides that are able to generate highly ordered 
structures from relatively unfolded monomeric units. Interestingly, it was found that a large 
number of peptides and proteins with highly variable primary sequences are capable of forming 
fibrils with similar structural characteristics given the right conditions. The remarkable stability 
of fibrils can be attributed mainly to the complex arrangement of hydrogen-bonded β-sheets 
closely interacting with each other. 
1.2.2 Fibril morphology and structure  
Amyloid fibrils are thread-like structures usually about 7–13 nm in diameter. The length of 
fibrils varies greatly; usually fibrils are around 100 nm to 1000 nm long. Amyloid fibrils are 
typically composed of a number (usually 2 to 8) of protofilaments that twist around each other, 
however, the types of lateral association can significantly differ. Some fibrils are formed by just 
a single protofilament,1,74,75 whereas other proteins can form highly associated fibrillar 
structures (Figure 1). The morphological types can also differ depending on the external 
conditions (pH, ionic strength, etc.).55  
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Figure 1: Morphology of an amyloid fibril of transthyretin(105-115) fragment. The fibril structure was 
obtained from solid-state NMR and cryo-electron microscopy data. The fibril consists of six protofilaments each 
shown in different colour. PDB ID: 2M5K, (Fitzpatrick 2013)76 
Mature amyloid-like fibrils have a so-called ‘cross β-sheet structure’ composed of parallel, in-
register β-strands. The peptide/protein backbone runs perpendicular to the fibre axis in each 
protofilament and forms a β-strand along the fibre. β-strands stack together by hydrogen 
bonding of their amide N-H and C=O groups forming a β-sheet. In contrast to the non-repetitive 
β-sheets seen in native proteins, amyloid β-sheets consist of multiple copies of identical 
polypeptide chains, which leads to symmetrical patterns in their assembly (Figure 2). The 
amide group in the side chains of glutamine and asparagine residues can also form in-register 
hydrogen bonds between different β-sheet layers, creating hydrogen-bonded ladders. Other side 
chains, such as tyrosine, serine and threonine, can also contribute to ladder formation. This 
cross- structural motif can be detected by ‘amyloid specific’ fluorescent dyes, such as 
thioflavin T (ThT), Congo red or their derivatives. Structural models of amyloid fibrils suggest 
that ThT binds by aligning itself parallel to the long axis of the fibre and it intercalates into the 
repeating side chain interactions within a β-sheet layer.8  
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Figure 2: Protofilament of Aβ(1-42) peptide. An atomic model was obtained from solid-state NMR data. Each 
peptide chain is coloured differently. PDB ID: 2MXU (Xiao 2015)77 
1.2.3 Intermediate species (oligomers) and their structures 
In contrast to fibrils, which generally all have a similar cross- structural motif, oligomers that 
are formed during the aggregation process vary widely in their size and structure. These 
oligomers can also have different roles in the aggregation process. They can be formed as on- or 
off-pathway intermediates either in the process of fibrillation and/or as a consequence of 
secondary nucleation on the surface of pre-formed fibrils.78,79 Stable misfolded oligomers have 
been found during the aggregation of a variety of proteins,55,80–82 yet it is not entirely clear 
whether these stable/metastable oligomers are obligatory or optional precursors of amyloid 
fibrils, or whether they are an alternative folding product competing with the fibrillation 
pathway.  
Many independent studies have shown that the size of oligomers and the level of exposure of 
hydrophobic residues within them play an important role in their cytotoxicity.1,83–85 It was found 
that toxicity generally decreases with increasing oligomer size and that oligomers with a higher 
percentage of solvent-exposed hydrophobic residues tend to have higher toxicity. This is mainly 
because of their interaction with the lipid bilayers of biological membranes.1,5 
Oligomeric species populated during the aggregation process are often challenging to 
characterise due to their low abundance and transient nature. Moreover, depending on the 
experimental conditions, multiple types of oligomeric species are often formed, including 
possible polymorphisms of oligomers of the same size. In the case of intrinsically disordered 
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systems, e.g. the Aβ peptide or α-synuclein, oligomers formed early during aggregation have 
generally a disordered structure and more highly organised oligomers appear in the later stages 
of the reaction (Figure 3). Similarly, early aggregates in the fibrillation of initially globular 
proteins preserve a more native-like structure of the monomers that later converts to a β-sheet 
structure.7,86–90 Early aggregates are typically of low molecular weight and do not bind ThT or 
Congo red dyes. 
 
Figure 3: Three-dimensional reconstruction of oligomers isolated during α-synuclein aggregation. 
Oligomers are approximately 260 kDa and 420 kDa in size corresponding to circa 18-mer and 29-mer, respectively. 
Adapted from (Chen 2015).68 
1.2.4 Kinetic models of fibrillation  
In 1989, Naiki et al.91 quantified amyloid fibrils in vitro by spectrophotometric detection of the 
fluorescence emission of thioflavin T using the linearity between the concentration of fibrils 
and the fluorescence emission intensity at 480 nm that ThT displays when bound to the 
β-sheet-rich structure of fibrils. Since then, ThT assays have been widely used for the 
investigation of the kinetics of amyloid fibril formation. 
The fibrillation process generally proceeds via a multi-step mechanism: First, the monomeric 
peptides self-associate to oligomeric structures, and these further elongate to form amyloid 
fibrils. A classical fibrillation exhibits sigmoidal kinetics with three distinct phases — a lag 
phase (during which nucleation takes place), a growth phase (which consists of elongation and 
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secondary nucleation processes) and a plateau phase (where monomer is completely depleted 
or equilibrium is reached).92–95 However, none of these phases can be ascribed to a single type 
of molecular event or microscopic process (e.g., nucleation, elongation, fragmentation etc.). All 
of the microscopic processes are present in all phases to some extent, although their prevalence 
can vary significantly with time. Monomeric species dominate in the lag phase and fibrils in 
the plateau phase, while during the growth phase their concentrations can be similar.95 A typical 
sigmoidal ThT fluorescence aggregation profile assuming a nucleation-polymerization model 
is depicted in Figure 4, which also shows approximate boundaries of the individual phases and 
illustrates the meaning of the kinetic parameters. The slope of the apparent growth can vary 
depending on the dominant underlying secondary processes. 
 
Figure 4: Sigmoidal aggregation kinetics and kinetic parameters. 
The ThT aggregation curves can be empirically described by the equation 1.1: 
𝑌 = 𝑌0 +
𝐴
1 + e−𝑘(𝑡−𝑡1/2)
(1.1) 
 ,where Y0 is the initial fluorescence, A is the maximal amplitude in the plateau phase relative 
to Y0, t1/2 is the half-time, which is defined as the time when ThT fluorescence has reached 50% 
of its maximal amplitude, k represents the apparent growth rate.8,12,96 The lag time can be 
obtained from the kinetic parameters using equation 1.2: 
𝑡lag = 𝑡1/2 −
2
𝑘
(1.2) 
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Primary nucleation 
The process during which new aggregates are formed directly from soluble monomers is known 
as primary nucleation (Figure 5). The rate-limiting step is the formation of a sufficient number 
of critical nuclei and the reaction is highly dependent on the monomer concentration. Primary 
nucleation is also usually very slow in the absence of extrinsic factors such as agitation.97 
Primary nucleation is the first process that proceeds at the onset of the lag phase, and it is usually 
accompanied by the secondary processes as soon as any fibrils are formed. 
Secondary processes 
The main characteristic of the secondary processes is the formation of new fibrils with the aid 
of the already existing ones. Therefore, the rate of fibril formation is proportional to the overall 
mass of fibrils in the sample. This leads to a rapid exponential growth following the lag phase, 
which is a typical behaviour of these processes. This growth is likely to play a significant role 
in spreading of amylogenic diseases within an organism.1 There are several types of secondary 
processes and their occurrence and ratio depends on the system of interest and the exact 
conditions. Among the most common secondary processes are surface-catalysed secondary 
nucleation and fragmentation (Figure 5).  
In a surface-catalysed secondary nucleation process, the fibrillation is catalysed by the surface 
of already existing fibrils. Since both monomers and fibrils are needed for this secondary 
nucleation process, its maximal rate occurs around the half time in the growth phase of the 
aggregation reaction, where both species are highly populated. New fibrils are formed from 
monomers and the process generates a positive feedback loop since increasing the number of 
fibrils also increases the available catalytic surface.98,99 Moreover, it was reported that other 
biological surfaces are also able to catalyse the nucleation step in amyloid formation, e.g. cell 
membranes as in the case of α-synuclein aggregation.100 
Fragmentation refers to the process in which a growing fibril breaks into smaller fragments, 
which increases the number of elongation sites, and the fibrillation process is, therefore, faster. 
This process often depends on external factors, such as sonication or stirring.97 Fragmentation 
of fibrils has been observed in actin filaments,101 and in both yeast and mammalian prions.92,102 
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Figure 5: Fibrillation mechanisms — nucleation pathways. Adapted from (Dobson 2019).2 
Off-pathway aggregation — Non-fibrillar oligomers in peptide and protein aggregation 
Non-fibrillar aggregates have often been observed in fibrillation processes, populated both 
before and during fibril formation. So far, the exact effect of non-fibrillar species on the 
fibrillation process has not been fully explored. It is generally assumed that their effect on the 
fibrillation kinetics depends on their role in the mechanism and that non-fibrillar oligomers can 
be broadly divided into two categories.67 Oligomers can be either on-pathway, which means 
that they are capable of directly converting to fibrils, or they can be off-pathway, i.e. incapable 
of direct conversion to fibrils (Figure 6). 
 
Figure 6: Nucleation-polymerization and off-pathway oligomer mechanism. Comparison of the on-pathway 
(A) and off-pathway (B) fibrillation mechanism. Adapted from (Zapadka 2017).6 
A
B
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Off-pathway aggregates affect fibrillation through their equilibrium with the monomer. They 
limit the concentration of the monomer available for fibril formation and as the monomer gets 
depleted by fibrillation, these aggregates release monomers back into the solution to preserve 
the equilibrium. This reduction in the available monomer concentration slows down the 
fibrillation process. For example, the formation of off-pathway oligomers was used to explain 
the unusual dependence of the aggregation kinetics on the peptide concentration observed for 
GLP-112 and liraglutide,26 where in both cases the fibrillation process slows down with 
increasing peptide concentration. For some peptides, formation of off-pathway oligomers and 
even of off-pathway short curvi-linear fibrils was observed above a certain concentration 
threshold, called the critical oligomer concentration. It was also shown that these off-pathway 
species are not precursors of the classical late-stage rigid fibrils.55 
1.3 Glucagon-like peptide 1 (GLP-1) and its aggregation 
properties 
Nowadays, GLP-1 analogues are commonly used as drugs for type 2 diabetes treatment. 
However, there are many issues arising due to GLP-1 instability during the manufacturing 
process as well as in vivo. Therefore, pharmaceutical companies are trying to develop effective 
GLP-1 analogues with improved physical stability and long-acting effects. The main issues 
regarding GLP-1 stability are its high propensity to aggregate under a wide range of conditions 
and short plasma life-time due to enzymatic degradation. These issues are among the current 
challenges of the pharmaceutical industry.103 
1.3.1 Physiological role of GLP-1 
GLP-1 belongs to the incretins family of gastrointestinal peptide hormones.104 This peptide 
hormone is responsible for many regulatory mechanisms affecting the glucose level in blood. 
In healthy patients, GLP-1 is secreted from intestinal endocrine L-cells, where the proglucagon 
gene is expressed and further processed,105 and the secretion is stimulated by food ingestion. 
The full peptide has 37 amino acids, however, it becomes bioactive only after a cleavage of the 
first six N-terminal residues. The two major bioactive forms circulating in blood are 
GLP-1(7-37) and GLP-1(6-36)NH2. The latter, GLP-1(6-36)NH2, is the prevailing (about 80%) 
active form of the hormone in blood.106 Naturally, GLP-1 stimulates meal-induced insulin 
release from the pancreas and inhibits glucagon release from the liver (Figure 7). Moreover, it 
positively influences all steps in insulin biosynthesis. Overall, GLP-1 is able to reduce 
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hyperglycemia in type 2 diabetic patients, and therefore GLP-1 analogues are considered to be 
promising candidates for type 2 diabetes mellitus treatment.  
Recent studies have shown a potential use of GLP-1 in obesity treatment due to its ability to 
reduce appetite. It has been shown that GLP-1 administration inhibits food intake in rodents 
which suggests that GLP-1 may directly affect the brain. This is supported by the finding that 
GLP-1 circulating in blood can access GLP-1 receptors in certain brain areas that are involved 
in the regulation of appetite and in energy homeostasis.106 
 
Figure 7: Functions of GLP-1 in humans. Adapted from (Drucker 2006).106 
1.3.2 Analogues of GLP-1 
To overcome the problem of GLP-1 instability, pharmaceutical companies are developing 
GLP-1 analogues with improved stability but similar therapeutic effects. The most promising 
strategies include lipidation, e.g.in liraglutide or semaglutide, which are shown in Figure 8, or 
antibody fragment conjugation like in dulaglutide. Many pharmaceutical companies are aiming 
to develop long-acting GLP-1 analogues with an easy way of administration (Figure 9). 
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Figure 8: Lipidated GLP-1 analogues. Structure of liraglutide and semaglutide. Adapted from (Lau 2015).107 
 
Figure 9: GLP-1 analogues in clinical and preclinical testing. Adapted from (Fosgerau 2015).10 
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1.3.3 Aggregation propensity of GLP-1 
It has been shown that GLP-1 forms amyloid fibrils under a wide range of conditions.12,13 
Previously, an unusual pH-dependent aggregation behaviour attributed to the formation of off-
pathway aggregates was reported by our group.12 Aggregation has also been observed for 
liraglutide.26  
Prediction of the aggregation prone regions of GLP-1 
Various algorithms have been developed to theoretically predict aggregation-prone regions 
(APRs) of peptides and proteins. Some examples of prediction software with a brief description 
of the methods are given in Table 1. Comparison of different APR predictions on GLP-1 
peptide is shown in Figure 10. 
Method Description 
TANGO34 Sequence-based statistical mechanics algorithm. The algorithm takes 
into account the hydrophobicity, solvation energies, electrostatic 
interactions and hydrogen bonding of each residue. 
3D Profile 
Method39 
Structure-based method. Each six-residue protein segment is mapped 
onto a set of templates generated from the crystal structure of a small 
NNQQNY peptide fibril. The energy of each mapping is evaluated 
using ROSETTADESIGN, and the lowest energy match for a given 
peptide is taken as the prediction. If the energy of the structure is lower 
than a threshold value, a prediction for fibrillation is made.  
CamSol Intrinsic38 Sequence-based method focused on the solubility of peptide regions 
which correlates with the aggregation propensity. The score is given 
on the basis on the hydrophobicity, charge, α-helix and β-stand 
propensity of a residue taking into an account 7 neighbouring residues. 
Table 1: Software for the prediction of aggregation prone regions in peptides and proteins. 
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Figure 10: GLP-1 aggregation-prone region predictions. Comparison of TANGO algorithm (A) 3D Profile 
Method (B) and CamSol method (C). In TANGO algorithm and CamSol method prediction was done using a 
theoretical pH value of 8. The red colours in B and C indicate the highest propensity for fibrillation and the lowest 
solubility, respectively. 
Predictions by both TANGO and CamSol methods show the GLP-1 fragment between the 
phenylalanine at position 22 and the valine at position 27 (i.e. the FIAWLV segment) has the 
highest propensity for fibrillation. However, the 3D Profile Method identified the region 
containing the aspartic acid (at position 9) and adjacent residues as the one with the highest 
propensity for aggregation (Figure 10). 
1.4 Aims of the M.Phil. research 
Studies previously conducted by our group have found that GLP-1 has a high propensity for 
fibrillation under a wide range of conditions.12 However, under some conditions, the 
aggregation kinetics do not follow the classical nucleation-polymerization mechanism. Based 
on experimental kinetic data, a mechanism with a metastable off-pathway intermediate species 
was proposed for this system.12  
A
B
C
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The main aim of the research presented in this Thesis is to study the aggregation behaviour of 
a C-terminally amidated analogue of GLP-1, GLP-1-Am, at neutral and basic pH. Previous 
work conducted in our group showed that the C-terminal amidation of GLP-1 significantly 
slows the aggregation rate, however, it does not prevent it completely. Moreover, at basic pH 
values GLP-1-Am showed a large variance in aggregation kinetics.13 The work presented here 
sets out to investigate the aggregation kinetics under these conditions and, as far as possible, 
identify and characterise the intermediate species populated during the aggregation process. 
In the following chapters, the kinetics of fibrillation was investigated using thioflavin T binding 
assays. The formation of small soluble oligomers as well as depletion of the monomeric peptide 
during the aggregation was monitored by size-exclusion chromatography. Analytical 
size-exclusion chromatography was also used for size determination, separation and assessment 
of the stability of the oligomeric species. The stability of the oligomers was also tested using 
sodium dodecyl sulfate polyacrylamide gel electrophoresis. The structure of oligomers and 
fibrils formed was investigated using circular dichroism and fluorescence spectroscopies. The 
presence of fibrils was shown by scanning electron microscopy. 
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Peptide 
The 31-residue GLP-1(7-37), HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG, and its 
C-terminally amidated version GLP-1-Am(7-37) were purchased from Bachem in the form of 
an acetate salt with 98.5% and 96.7% purity, respectively, and used without further purification. 
The molecular weight of both peptides is approximately 3355 Da. 
Buffers 
All buffers were prepared using the appropriate acids and salts of analytical grade purchased 
from Sigma-Aldrich or Fisher Chemicals with distilled deionized water (at a resistivity of 
18.2 MΩ cm at 25 °C) in volumetric glassware and filtered through 0.22 µm pore size 
membrane (PES or PVDF membranes, Millex). All buffers were prepared gravimetrically 
without further pH adjustment. The pH of buffers was checked using a PHM210 pH meter 
(Radiometer Analytical). 
Buffer acid and salt amounts were calculated using the Henderson-Hasselbalch equation and 
the conservation of molar amount: 
pH =   p𝐾a + log (
[A−]
[HA]
) (2.1) 
[A−] + [HA] = 𝑐buffer (2.2) 
where [A-] is the concentration of the basic buffer component, [HA] is the concentration of the 
acidic buffer component (dissociation in solution was neglected) and cbuffer is the total buffer 
concentration. 
The ionic strength (I) of buffers was calculated using: 
I =
1
2
∑ 𝑐𝑖𝑧𝑖
2
𝑖
(2.3) 
where ci is the molar concentration of ion i, zi is the charge number of the ion i, and the sum is 
taken over all types of ions in the solution. 
Composition of buffers for aggregation assays and biophysical measurement: 
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Sodium phosphate buffer, 25 mM at pH 8 (ionic strength ≈ 71 mM) was prepared by dissolving 
0.638 g of NaH2PO4 · 2 H2O (MW: 156.01 g mol
-1) and 3.259 g of Na2HPO4 
(MW: 141.96 g mol-1) in distilled deionized water. The pKa value was 6.95. 
This buffer was used for sample incubation during aggregation reactions, analytical size-
exclusion chromatography calibration curves and sample analysis on size-exclusion columns. 
Tris buffer, 25 mM at pH 8.2 at 37 °C (ionic strength ≈ 7 mM) was prepared by dissolving 
1.085 g of Trizma® hydrochloride (MW: 157.6 g mol-1) and 2.194 g of Trizma® base (MW: 
121.14 g mol-1) (both SigmaAldrich). The pKa at this temperature is 7.78 (37 °C). For 
experiments at 25 °C, where the pKa is 8.12, buffer calculations were performed analogously 
(ionic strength of the resulting buffer ≈ 11 mM). 
Tris buffer, 25 mM at pH 8.5 at 37 °C (ionic strength ≈ 4 mM) was prepared by dissolving 
0.631 g of Trizma® hydrochloride (MW: 157.6 g mol-1) and 2.544 g of Trizma® base 
(MW: 121.14 g mol-1) (both SigmaAldrich). The pKa of Tris is 7.78 (37 °C). For experiments 
at 25 °C, the pKa of Tris is 8.12 and buffer calculations were performed analogously (ionic 
strength of the resulting buffer ≈ 7 mM).  
Other chemicals 
Thioflavin T (ThT) was purchased from Sigma-Aldrich. The dye content in the powder was 
≥65%. A stock solution was prepared in distilled deionized water in 5 mM concentration. The 
ThT stock was filtered through a 0.22 µm filter (PES membrane, Millex) and stored at -20 °C.  
8-Anilo-1-naphthalene-sulfonatic acid (ANS) was purchased from Sigma-Aldrich with ≥97% 
purity. A stock solution was prepared in distilled deionized water in 9.84 mM concentration. 
ANS stock was filtered through 0.22 µm filter (PES membrane, Millex) and stored at -20 °C. 
The concentration of ANS was determined spectrophotometrically using the absorbance at 
350 nm and the extinction coefficient ε350 = 5000 cm-1 M-1.108 
Tween® 20, polyoxyethylene(20)sorbitan monolaurate, was purchased form Acros Organics. 
Phosphate buffer with 1% Tween (v/v) was prepared prior to the sample incubation/aggregation 
by pipetting corresponding volume of Tween® 20 to the 25 mM phosphate buffer at pH 8. 
Peptide sample preparation and aggregation 
The peptide powder was dissolved in 25 mM sodium phosphate buffer (pH 7–8) or 25 mM Tris 
buffer (pH 7.5–8.5). After peptide dissolution, the sample was filtered through a 0.22 µm filter 
(PES or PVDF membranes, Millex). The concentration of the peptide was determined 
photometrically on a Cary 60 UV-Vis spectrophotometer (Agilent Technologies) using the 
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Beer-Lambert law and a theoretical extinction coefficient of 6990 M-1 cm-1 at 280 nm. The 
extinction coefficients of GLP-1 and GLP-1-Am were calculated using the ExPASy 
Bioinformatics Resource Portal using: 
ε280 = 5500 𝑛Trp + 1490 𝑛Tyr + 125 𝑛S-S (2.4) 
where ε280 represents the extinction coefficient at 280 nm, nTrp is the number of tryptophan 
residues in the peptide sequence, nTyr is the number of tyrosine residues in the peptide sequence 
and nS-S is the number of disulfide bridges in the peptide sequence. Absorbance measurements 
were performed by scanning the sample between 200 and 400 nm and subtracting the absorption 
spectrum of the buffer measured in the same cuvette over the same wavelength range. For 
freshly prepared samples, no significant light scattering was observed (i.e. the absorbance at 
320 nm was close to zero) and, therefore, peptide concentration was calculated directly using 
A280 without further correction. 
Samples were incubated in 1.5 mL or 2.0 mL plastic microcentrifuge tubes (STARLAB) sealed 
and wrapped in aluminium foil to protect from sunlight. Incubation/aggregation was performed 
in an Incubator Shaker (Innova®43) at 37 °C at 80 rpm, 100 rpm or 180 rpm, or on a microplate 
reader FLUOstar Omega (BMG Labtech) plate (Corning 3881), sealed with tape (Costar 
Thermowell) at 37 °C, with 5 minutes of shaking every 30 minutes (orbital shaker mode at 600 
rpm). 
Oligomers were separated from the solution either by filtration though a 0.22 µm filter (PES or 
PVDF membranes, Millex) that removed all large insoluble aggregates or by size-exclusion 
chromatography where the oligomer-containing fractions were subsequently concentrated in 
3 kDa MWCO cellulose Amicon® Ultra centrifugal filters 0.5 mL (Merck Millipore) or in 
Vivaspin 6, 3 kDa MWCO 3 mL (GE Healthcare). 
Size-exclusion chromatography 
Analytical size-exclusion chromatography was performed on an ÄKTA FPLC system (GE 
Healthcare), using a Superose 12 10/300 or a Superdex 75 10/300 column (both GE 
Healthcare). Samples were loaded using 100 µL or 200 µL loops. Prior to loading, the samples 
were filtered through a 0.45 µm filter. All samples were eluted at a flow rate of 0.75 mL min-1 
at room temperature and UV absorbance detection at 280 nm through a 0.5 cm flow cell was 
used. Globular protein standards were used for column calibration under the same conditions 
as the experiments for the GLP-1-Am oligomers. The elution volume of each protein standard 
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was plotted against the logarithm of its molecular weight. A linear regression of this plot was 
used to determine the molecular weight of the observed GLP-1-Am oligomers. 
Circular dichroism 
Circular dichroism spectra were measured on a Chirascan CD spectrometer (Applied 
Photophysics). All measurements were performed with 1 nm step size and with 1 nm spectral 
bandwidth at room temperature. Far-UV CD spectra over the range 180–250 nm were measured 
in 1 mm or 0.1 mm pathlength cuvettes. Near-UV CD spectra over the range 250–350 nm were 
measured in 2 mm pathlength cuvettes. The resulting spectrum was obtained as an average of 
three identical scans and the spectrum of the pure buffer was subtracted. 
Kinetics of aggregation — Thioflavin T binding assays 
Fluorescence kinetic measurements were carried out using a microplate reader FLUOstar 
Omega (BMG Labtech). Peptide samples at a given concentration were incubated at 37 °C with 
50 µM concentration of ThT. Peptide samples with ThT were pipetted into a 96-well half-area 
plate (Corning 3881) and sealed with tape (Costar Thermowell) to prevent samples from 
evaporation. The total volume of each sample in a well was 100 µL. Bottom reading of the plate 
was performed every 30 minutes with 5 minutes of shaking prior to each reading (orbital shaker 
mode at 600 rpm). ThT binding to fibrils was monitored by recording the fluorescence emission 
at 482 nm with an excitation filter at 448 nm. Fluorescence was measured at a gain of 500 with 
8 flashes per well. 
Thioflavin T and 8-anilo-1-naphthalene-sulfonic acid binding experiments 
Binding of both 8-anilo-1-naphthalene-sulfonic acid (ANS) and ThT were measured using a 
Cary Eclipse Fluorescence Spectrophotometer (Agilent Technologies). For ThT binding 
experiments, spectra were obtained by excitation at 448 nm and emission was recorded in the 
range 460–600 nm with a step of 1 nm. The ThT concentration in the samples was 50 µM. 
ANS fluorescence emission was recorded in the range from 400 to 600 nm after excitation at 
350 nm. ANS concentration in all samples was 250 µM. 
Intrinsic tryptophan fluorescence 
Intrinsic tryptophan fluorescence spectra were measured on a Cary Eclipse Fluorescence 
Spectrophotometer (Agilent Technologies). Spectra were obtained using an excitation 
wavelength of 280 nm and emission spectra were recorded between 300 and 400 nm with a step 
of 1 nm. Emission and excitation band passes of 10 nm, and a voltage on the photomultiplier 
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tube of 550 V were used. Samples were measured in a 120 µL quartz cuvette (Hellma 
Analytics). 
Denaturing protein gel electrophoresis 
The non-covalent character of GLP-1-Am oligomers was assessed by sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) using a pre-cast 4–12% Bis-Tris gels 
(Life Technologies) run in NuPAGE® MES SDS Running buffer (Life Technologies) for 35 
minutes at a constant voltage of 200 V. Peptide samples were prepared in NuPAGE® LDS 
Sample buffer (Life Technologies), heated for 5 minutes to 95 °C and immediately loaded onto 
the gel. Protein and peptide standards, Mark 12 Unstained Standard and PageRuler Unstained 
Protein Ladder (both ThermoFisher Scientific), were run in parallel for size reference. Gels 
were stained with InstantBlue (Expedeon). 
Scanning electron microscopy  
A single drop of the sample was spread onto a microscope glass slide which was previously 
washed with isopropanol and acetone and then dried. The sample was left to dry and the excess 
salts were washed by rinsing the glass slide gently with 300 µL of distilled deionized water two 
times. Prior to the imaging, the samples were dried under a stream of nitrogen and coated with 
a 10 nm layer of platinum using a Quorum Technologies Q150T ES Turbo-Pumped Sputter 
Coater/Carbon Coater. Scanning electron microscopy (SEM) images were taken with a MIRA3 
instrument (TESCAN) at 5.0 kV using an In-Beam Secondary Electron detector. 
Assessment of oligomer stability 
Oligomer stability testing was performed using size-exclusion analytical columns 
Superose 12 10/300 and Superdex 75 10/300. For elution at pH 8, a 25 mM sodium phosphate 
buffer was used and at pH 8.5 and 8.2, a 25 mM Tris buffer was used. Samples containing 
isolated oligomers or a mixture of the monomer and oligomeric species were either heated, 
sonicated or incubated with an organic solvent (20% isopropanol, 30% and 40% acetonitrile) 
for a specified time. Immediately after this, samples were run on a buffer-equilibrated SEC 
column at room temperature. 
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In this Chapter the aggregation behaviour of glucagon-like peptide 1 amide (GLP-1-Am) at pH 
values from 7 to 8 is described. In this pH range, C-terminal amidation of GLP-1 was shown to 
have the greatest effect on the aggregation behaviour. Compared to non-amidated peptide, 
C-terminal amidation significantly slows fibrillation under these conditions, however, it cannot 
prevent it completely.13 Most of the experiments in this Chapter were performed at pH 8 in 
25 mM sodium phosphate buffer, however, a very similar behaviour was also observed at pH 7 
and 7.5 (Appendix A). 
3.1 GLP-1-Am shows significantly lower propensity to aggregate 
at pH 7–8 than GLP-1 
To monitor and compare the aggregation behaviour of GLP-1 and GLP-1-Am, peptide samples 
were incubated with ThT at 37 °C for approximately one week with shaking at 600 rpm for 
5 minutes prior to each fluorescence reading. During this time, ThT emission at 482 nm (after 
excitation at 448 nm) was monitored as a measure of fibril formation. In accordance with the 
previous study,13 it was observed that in the range of pH between 7 and 8, the aggregation 
properties of GLP-1-Am differ greatly from those of GLP-1. This is apparent from the 
significantly prolonged lag times as well as the shape of the ThT fluorescence curve over time. 
Moreover, while GLP-1 shows a typical sigmoidal aggregation curve with a rapid elongation 
phase after a critical number of nuclei is formed, GLP-1-Am aggregation curves lack the rapid 
rise in fluorescence due to the elongation and growth phases, and the increase in fluorescence 
is rather slow and gradual when compared with GLP-1 at the same peptide concentration 
(Figure 11). Therefore, it is not possible to extract any kinetic parameters, e.g. k, t1/2, for the 
aggregation of amidated GLP-1 at pH 8 over 145 hours. This suggests a significantly lower 
propensity to aggregate compared with GLP-1 under the same conditions. 
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Figure 11: Aggregation of GLP-1 and GLP-1-Am at pH 8 in 25 mM sodium phosphate buffer monitored by 
ThT at 37 °C. Aggregation assay was performed using a microplate reader FLUOstar Omega. Runs in triplicate 
are shown. Yellow: GLP-1 85 µM; Green: GLP-1 42.5 µM; Blue GLP-1-Am 85 µM; Red: GLP-1-Am 42.5 µM. 
3.2 GLP-1-Am forms small oligomers during the long lag phase 
Samples of 85 µM GLP-1 and GLP-1-Am were analysed by SEC, during their incubation at 
37 °C using constant double orbital shaking at 80 rpm. Before the SEC analysis, the sample 
was filtered through a 0.45 µm filter to remove fibrils and large insoluble aggregates which 
would block the filter of the SEC column. Using a Superose 12 SEC column, it was possible to 
monitor depletion of monomeric peptide during the aggregation reaction. Moreover, the column 
matrix was able to resolve the monomer from the peaks of small oligomers, which were formed 
during the aggregation, and thus monitor their formation over time.  
Significant differences were observed between GLP-1 and GLP-1-Am in the monomer 
depletion rate. GLP-1 shows fast depletion of the monomer over time compared to GLP-1-Am. 
In addition, during the incubation/aggregation time oligomers were detected for GLP-1-Am but 
not for GLP-1. After 48 hours of incubation, oligomers of GLP-1-Am start to appear and 
gradually increase over time as shown in Figure 12.  Presumably, for GLP-1, the monomer is 
quickly converted into the amyloid fibril or other large insoluble aggregates that are removed 
by filtration prior to the SEC analysis.  
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Figure 12: Size-exclusion chromatographic analysis of the population of the monomer and small oligomers 
during the aggregation of GLP-1 and GLP-1-Am. GLP-1 (A) and GLP-1-Am (B) monomer depletion and 
oligomer formation was monitored over time by SEC. Samples at an initial concentration 85 µM (both GLP-1 and 
GLP-1-Am) incubated at 37 °C with continuous shaking at 80 rpm were analysed on a Superose 12 10/300 size-
exclusion column in 25 mM sodium phosphate buffer at pH 8 at room temperature. In the case of GLP-1, the only 
peak was eluted at approximately 16.9 mL corresponding to the monomer. For GLP-1-Am, there is only one peak, 
most likely monomeric, at the beginning of incubation (0 h) at approximately 17.7 mL. After 48 hours incubation, 
peaks with lower retention volumes (approximately 15.5 mL and 16.2 mL), corresponding to small oligomers, 
start to appear. 
For GLP-1-Am the single peak at approximately 17.7 mL most probably corresponds to the 
monomeric peptide. The peaks at the lower elution volumes (approximately 15.5 and 16.2 mL) 
correspond to species with higher molecular masses compared to the monomer. This suggests 
that they are peptide oligomers that were formed during the aggregation process. It is important 
to note that under the conditions used, there were not only the monomer and the oligomers 
present but also amyloid fibrils and possibly other insoluble aggregates were formed as was 
shown by scanning electron microscopy (SEM) in Figure 24 (this Chapter, section 3.7). These 
larger species were removed by the filtration step prior to the SEC and therefore are not 
observed in the SEC experiment.  
3.3 Determination of the size of GLP-1-Am oligomers 
In order to determine the size of the GLP-1-Am oligomers formed during the aggregation 
reaction, the calibration of two different SEC columns under the same conditions was 
performed using globular protein standards of a defined size in 25 mM sodium phosphate buffer 
at pH 8, 0.75 mL min-1 flow rate. 
Calibration curve for Superose 12 10/300 in 25 mM sodium phosphate 
buffer at pH 8. 
The void volume of the column was determined using Blue dextran 2000 and was 7.7 mL. A 
set of globular proteins (Table 2) was used for calibration (Figure 13). The total volume of a 
Superose 12 10/300 column is 19.7 mL. The elution volumes of protein standards were plotted 
oligomers
-0.2
4.8
9.8
14.8
19.8
24.8
13 14 15 16 17 18 19 20 21
A
2
8
0
 [
m
A
U
]
Volume [mL]
0 h
48 h
72 h
144 h
12 days
16 days
monomer
-0.2
4.8
9.8
14.8
19.8
24.8
29.8
13 14 15 16 17 18 19 20 21
A
2
8
0
 [
m
A
U
]
Volume [mL]
0 h
24 h
48 h
96 h
144 h
GLP-1 GLP-1-Am
A B
oligomers
Chapter 3  
GLP-1-Am aggregation at pH 7–8 
27 
 
against the logarithm of their molecular weight and the correlation was described by a linear 
regression fit and its square of the correlation coefficient, where Ve is the protein elution volume 
measured from the centre of a peak. 
Protein standard MW [Da] Elution volume [mL] 
Aldolase 158,000 11.4 
Conalbumin 75,000 12.2 
Ovalbumin 44,000 12.6 
carbonic anhydrase 29,000 13.9 
Trypsinogen 24,000 14.5 
ribonuclease A 13,700 15.1 
chymotrypsin inhibitor 2 9,265 15.9 
GLP-1-Am monomer 3,355 17.7 
Table 2: Protein standards and their elution volumes on a Superose 12 10/300 in 25 mM sodium phosphate 
buffer at pH 8. 
 
Figure 13: Superose 12 10/300 column calibration curve. Calibration performed in 25 mM sodium phosphate 
buffer at pH 8 on a set of protein standards (Table 2) at room temperature. Elution was performed with a flow rate 
0.75 mL min-1 and 100 µL of approximately 100 µM of each protein was injected using a 200 µL injection loop. 
The blue dotted line is the linear regression fit, see below.  
𝑙𝑜𝑔10(MW/Da) = −0.2285 ⋅ 𝑉e + 7.6579 
𝑅2 = 0.9565 
3.6
3.8
4.0
4.2
4.4
4.6
4.8
5.0
5.2
5.4
11 12 13 14 15 16 17
lo
g 1
0(
M
o
le
cu
la
r 
w
ei
gh
t)
 [
D
a]
Elution volume [ml]
Chapter 3  
GLP-1-Am aggregation at pH 7–8 
28 
 
The elution volumes of the GLP-1-Am oligomers (Figure 14) were 15.5 mL for oligomer A 
and 16.2 mL for oligomer B. Using the equation above, the size of oligomer A was calculated 
as 13 kDa and 9 kDa for oligomer B. 
 
 
 
 
 
 
 
 
 
 
 
Calibration curve for Superdex 75 10/300 in 25 mM sodium phosphate 
buffer at pH 8. 
The void volume of the column was determined using Blue Dextran 2000 and was 8.2 mL. A 
set of globular proteins (Table 3) was used for calibration curve points (Figure 15). The total 
volume of the Superdex 75 10/300 column is 18.1 mL. The protein standards elution volumes 
were plotted against the logarithm of their molecular weight and the correlation is described by 
a linear regression fit and its square of the correlation coefficient, where Ve is the protein elution 
volume measured from the centre of a peak. 
Protein standard MW [Da] Elution volume [mL] 
Ovalbumin 44,000 9.8 
carbonic anhydrase 29,000 11.4 
Trypsinogen 24,000 12.1 
ribonuclease A 13,700 13.3 
chymotrypsin inhibitor 2 9,265 14.4 
GLP-1-Am monomer 3,355 17.1 
Table 3: Protein standards and their elution volumes on a Superdex 75 10/300 in 25 mM sodium phosphate 
buffer at pH 8. 
Figure 14: Elution profiles of the GLP-1-Am monomer and oligomers on a Superose 12 column. The 
sample was analysed prior to the incubation (0 h, blue line) and after 16 days (red line) of incubation at 37 °C 
with continuous shaking at 80 rpm. Elution conditions: 25 mM sodium phosphate buffer at pH 8, flow rate 
0.75 mL min-1, Superose 12 10/300. 
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Figure 15: Superdex 75 10/300 calibration curve. Calibration performed in 25 mM sodium phosphate buffer at 
pH 8 on a set of protein standards (Table 3) at room temperature. Elution was performed at a flow rate of 
0.75 mL·min-1 and 100 µL of approximately 100 µM of each protein was injected using a 200 µL injection loop. 
The blue dotted line is the linear regression fit, see below. 
𝑙𝑜𝑔10(MW/Da) = −0.1571 ⋅ 𝑉e + 6.232 
𝑅2 = 0.9935 
The elution volumes of the GLP-1-Am oligomers (Figure 16) were 14.4 mL for oligomer A 
and 15.3 mL for oligomer B. Using the equation above, the size of oligomer A was calculated 
as 9.3 kDa and 6.7 kDa for oligomer B. 
 
Figure 16: Elution profiles of GLP-1-Am monomer and oligomers on a Superdex 75 column. Samples were 
analysed prior to the incubation (0 h, blue line) and after 7 days (red line) of incubation at 37 °C with continuous 
shaking at 180 rpm. Elution conditions: 25 mM sodium phosphate buffer at pH 8, flow rate 0.75 mL min-1, 
Superdex 75 10/300. 
Molecular weights of oligomer A and B, which were calculated on the basis of the 
corresponding column calibrations, vary between the two SEC columns used. The difference is 
most probably given by the slightly different properties of the column matrices. Superose 12 
matrix is composed of cross-linked agarose with an average matrix bead size of 8–12 µm and 
Superdex 75 is a composite of cross-linked agarose and dextran with an average matrix particle 
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size of 13 µm. The separation range of a Superose 12 column (1000–300000 Da) is also much 
broader than the separation range of a Superdex 75 column (3000–70000 Da). Therefore, the 
resolution of Superose 12 column may be less precise. However, results of both SEC columns 
indicate that eluted species are low molecular weight oligomers of a size range from 6.7 kDa to 
13 kDa. These values correspond to a range of species from peptide dimers (6710 Da) to peptide 
tetramers (13 420 Da). 
Although SEC data may provide a reasonable estimate of the size of the oligomeric species, 
further complementary size characterization techniques are needed. It is important to point out 
that calibration of the size-exclusion column is based on the separation of globular proteins 
according to their hydrodynamic radii. GLP-1-Am monomer and oligomers may not be fully 
globular and this could cause inaccuracies in the size estimates. Characterization by 
complementary techniques such as mass spectrometry will be subject of further research. 
3.4 Stability of GLP-1-Am oligomers 
In this Section, the stability of GLP-1-Am oligomers formed in 25 mM sodium phosphate 
buffer at pH 8 with continuous shaking at 180 rpm was investigated. Stability experiments were 
performed using analytical SEC and SDS-PAGE. Prior to the SEC, a sample containing either 
previously isolated oligomers or a mixture of the monomer and small oligomers was heated, 
sonicated or incubated with an organic solvent, followed by a SEC under the usual conditions 
(25 mM sodium phosphate buffer, pH 8) on buffer-equilibrated columns. 
As was shown earlier in this Chapter, the amount of the oligomers steadily increases with time 
and then, after depletion of the monomer, remains constant, i.e. no backwards transformation 
into fibrils or monomers was observed (Figure 12). A series of stability experiments was 
performed using SEC (Figure 17).  
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Figure 17: Stability of small oligomers formed by GLP-1-Am. SEC elution curves before (blue line) and after 
(red line) a stability test. Samples A and C were analysed on a Superdex 75 10/300 column, and B and D on a 
Superose 12 10/300 SEC column. After incubation (in 25 mM sodium phosphate buffer at pH 8 with continuous 
shaking at 180 rpm, for 3–9 days), oligomeric peaks were first separated by SEC (for B, C, D only) and after the 
particular stability test analysed on an SEC column in 25 mM sodium phosphate buffer at pH 8. The samples were: 
A mixture of the monomer and oligomers sonicated for 50 min (A). Isolated oligomers incubated in 20% 
isopropanol for 1 hour (B), incubated in 40% ACN for 2 hours (C), or heated to 95 °C for 10 min (D). 
When the aggregating mixture containing both the monomer and small oligomers was sonicated 
for 50 min, the oligomeric peak remained unchanged, however, all the monomer was depleted, 
presumably converted into large aggregates (fibrils) as can be seen in Figure 17A. Therefore, 
sonication has the effect of intense agitation and speeds up fibrillation. Upon heating to 95 °C 
for 10 min, no significant change in the oligomeric peaks was observed (Figure 17D). 
Similarly, when small oligomers were incubated in 20% isopropanol for one hour, the 
oligomeric peaks were not significantly changed (Figure 17B). However, upon incubation in 
40% acetonitrile (ACN) for 2 hours, the oligomeric peaks decreased and small new peak of 
higher retention volume appeared (Figure 17C). This may imply a partial denaturation of small 
oligomers back to the monomer.  
Oligomeric fractions isolated using SEC were also tested by SDS-PAGE. Here, only one band 
corresponding to the molecular weight of the monomer was observed for the oligomeric 
samples (Figure 18). This suggests a complete denaturation of oligomers during SDS-PAGE. 
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Figure 18: SDS-PAGE analysis of GLP-1-Am oligomers formed at pH 8 in 25 mM sodium phosphate buffer. 
The oligomers were isolated (by SEC) from the 130 µM GLP-1-Am aggregated mixture incubated in 25 mM 
sodium phosphate buffer at pH 7.5 for 5 days at 37 °C with continuous shaking at 180 rpm. Lanes 2 and 4: 
GLP-1-Am oligomers; lane 6: fresh (monomeric) GLP-1-Am sample; lanes 1, 3, 5 and 7: proteins reference 
ladders. 
3.5 Structural characterization of GLP-1-Am oligomers 
GLP-1-Am oligomers were characterized using fluorescence spectroscopy and circular 
dichroism spectroscopy in the far- and the near-UV range. First, a far-UV CD spectrum of the 
peptide powder freshly dissolved in 25 mM sodium phosphate buffer at pH 8 was recorded and 
it shows that the monomeric peptide has some secondary structure (α-helix and β-sheet) as well 
as some disordered regions (Figure 19A). The secondary structure was predicted to be 
approximately 31% α-helix, 15% β-sheet, 23% turns and 31% disordered regions, using 
DichroWeb, Contin-LL method, dataset 3.109–111 In the previous studies conducted in our group, 
the secondary structure of the GLP-1-Am monomer was found to be approximately constant 
over a wide range of pH values with only a minor change between  pH 3 and 4.13 As expected, 
structural changes of the incubated mixture were observed over time. The overall spectrum after 
9 days of incubation of a sample containing a mixture of different chemical species (oligomers, 
monomer and fibrils), as was observed by SEC and SEM, is shown in Figure 19B. Interestingly, 
the spectrum of an isolated oligomeric species from mixture in Figure 19B has only a broad 
minimum around 200 nm corresponding to the disordered conformation (Figure 19C). In 
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contrast, a far-UV CD spectrum of solely fibrils (Figure 19D) shows a characteristic minimum 
around 220 nm, which reflects a large content of β-sheet. 
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Figure 19: Far-UV CD spectra of different chemical species present in the aggregating mixture of 
GLP-1-Am at pH 8 in 25 mM sodium phosphate buffer. CD intensity is presented in millidegree units due to 
difficulties in the determination of the concentration of fibrils and oligomers. All samples were measured in a 
0.1 cm pathlength cuvette. (A) GLP-1-Am monomer at 85 µM concentration, a freshly prepared sample. (B) GLP-
1-Am (85 µM) after 9 days incubation at 37 °C with constant shaking at 80 rpm. (C) GLP-1-Am oligomers isolated 
from sample B using SEC. (D) Fibrils isolated (by centrifugation) from a sample prepared analogously to sample 
B. All spectra were recorded at 25 °C. 
Interesting spectral features were also observed in the near-UV CD spectra (Figure 20). 
Whereas non-aggregated monomer does not have any signal in the near-UV CD region, fibrils 
show two sharp peaks at approximately 292 and 285 nm and a shoulder at around 280 nm. Since 
the near-UV spectral range in CD spectroscopy is associated with aromatic amino acid residues, 
a signal in this range can reveal structural information about the local environment of these 
residues. For the fibrils, the observed signal can be attributed mainly to the tryptophan residue 
(position 25 in the sequence) with a possible contribution from the phenylalanine (position 22). 
The appearance of the signal only in fibrillar structures can be explained by the fact that 
tryptophan residue is fixed in structure in this state restricting the rotation of its side chain. It is 
also possible that the signal is enhanced by exciton coupling of near-by tryptophan side chains 
from different peptide chains that are close in space in the amyloid fibril. Tryptophan exciton 
coupling usually has a characteristic pattern also in the far-UV region,112 however, in the case 
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of fibrils this pattern may be hidden by a strong signal from the fibril secondary structure. A 
similar interaction was observed by CD spectroscopy in some tryptophan zipper motifs.113,114 
Thus, the observed signal can be considered to be an indicator of a stable tertiary structure. The 
fact that tryptophan residues are in a fixed environment agrees with the findings of some of the 
theoretical predictions of the aggregation (fibrillation) prone regions (Chapter 1, Figure 10A, 
C). The absence of a CD signal in the near-UV range for oligomers indicates free rotation of 
the tryptophan residue in these structures. 
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Figure 20: Near-UV CD spectra of the chemical species present in the aggregating mixture of GLP-1-Am at 
pH 8 in 25 mM sodium phosphate buffer. CD intensity is presented in millidegree units due to difficulties in the 
determination of the concentration of fibrils and oligomers. All samples were measured in a 0.2 cm pathlength 
cuvette. GLP-1-Am monomer at 85 µM concentration (blue line); GLP-1-Am (85 µM) after 9 days of incubation 
with continuous shaking at 80 rpm (black line); GLP-1-Am oligomers isolated from the incubated sample by SEC 
(red line); Fibrils isolated (by centrifugation) from a sample prepared analogously to the sample with the black 
spectrum (green line). All spectra were recorded at 25 °C.  
Tryptophan fluorescence spectra are sensitive to the environment of the tryptophan residue 
giving information on its environment. Shift of the emission maxima (λmax) can reveal the extent 
of tryptophan exposure to the solvent. The wavelength λmax at 345 nm, Figure 21, observed for 
the peptide fibrils corresponds to tryptophans buried within a fibrillar structure. A significant 
red shift of λmax to 360 nm observed for the oligomers indicates a higher exposure of tryptophan 
side chains to the solvent suggesting an unfolded structure of the oligomers (Figure 21). The 
value of λmax of the oligomers is even higher than the value for the monomeric peptide which 
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may indicate a loss of the secondary structure present in the monomeric form, which can be 
seen by far-UV CD spectroscopy (Figure 19A).  
 
Figure 21: Emission spectra showing the maxima (λmax) of the intrinsic tryptophan fluorescence. The lowest 
λmax was observed for the folded structure of GLP-1-Am amyloid fibrils (green line), whereas the highest value for 
the unfolded oligomers (red line). All samples were measured in 25 mM sodium phosphate buffer at pH 8. 
Binding of thioflavin T and 8-anilinonaphtalene-1-sulfonic acid 
ThT and ANS are extrinsic fluorescent probes that can provide additional structural information 
about protein aggregates. ThT is known for its binding to the cross β-sheet structure present in 
amyloid fibrils.8 Upon binding to amyloid fibrils, ThT has a strong fluorescence emission 
maximum at around 482 nm after excitation at 450 nm.115 ANS binds to exposed hydrophobic 
patches present in some reported oligomeric species such as those formed by Aβ or islet 
amyloid polypeptide.116 These oligomeric species are often believed to be the main cytotoxic 
species in the aggregation process.117 Unbound ANS in solution weakly emits, after excitation 
at 350 nm, at around 530 nm. When bound to protein, its emission maximum is blue-shifted to 
approximately 470 nm and the emission intensity is greatly increased.118  
Here, it was shown that small oligomers of GLP-1-Am do not bind ThT, neither do they bind 
ANS (Figure 22). Even though the emission maximum of intrinsic tryptophan fluorescence at 
360 nm indicates an unfolded structure with exposed hydrophobic tryptophan residues, these 
oligomers are probably quite small, and therefore, do not have sufficient number of exposed 
hydrophobic residues to bind the ANS dye. The fact that oligomers do not bind ThT is in 
accordance with their structural characteristics as shown by far-UV CD with no evidence for 
any significant β-sheet structure. 
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Figure 22: Fluorescence spectroscopy: ThT and ANS binding to oligomers. Oligomers isolated using SEC 
(5 µM) do not show detectable binding of ThT (50 µM concentration in the sample) (A), or ANS (250 µM 
concentration in the sample) (B). All samples were measured in 25 mM sodium phosphate buffer at pH 8 at room 
temperature. 
3.6 The effect of 1% Tween® 20 on GLP-1-Am aggregation 
Non-ionic surfactants such as Tween® 20 or Tween® 80 are known for their capabilities of 
preventing protein aggregation induced by various types of mechanical stress.119 However, it 
has also been shown that addition of Tween® 20 to the solution of protein can increase the 
concentration of small protein aggregates. For example, Tween® 20 enhanced the formation of 
soluble aggregates of the recombinant human factor XIII, but prevented the formation of large 
insoluble aggregates.120 A similar effect was observed for the anti-L-selectin antibody where 
the addition of Tween® 20 promoted dimerization but inhibited the formation of higher-order 
aggregates.121 Further detection and characterization of the GLP-1-Am oligomers formed in the 
buffer with 1% Tween® 20 might, therefore, help us to explore the energy landscape of this 
peptide. 
The propensity to form soluble oligomeric species was shown when GLP-1-Am was incubated 
in sodium phosphate buffer at pH 8 with the addition of 1% non-ionic surfactant Tween® 20 
(v/v). After the addition of 1% Tween® 20 to 130 µM GLP-1-Am in phosphate buffer and 5 
days of incubation at 37 °C, an intense well-defined peak corresponding to a large oligomer 
species was detected alongside the peak of the monomeric peptide (Figure 23). The elution 
volume of the oligomeric peak is approximately 11.9 mL which corresponds to the size of circa 
86.8 kDa (≈ 26-mer). However, the presence of a surfactant may affect the elution profiles and 
the hydrodynamic radii of both the monomer and the oligomers. This may lead to earlier elution 
and an overestimation of the size of the species. 
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Figure 23: SEC of GLP-1-Am incubated in 1% Tween® 20. Elution chromatogram of 130 µM GLP-1-Am 
incubated in 25 mM sodium phosphate buffer at pH 8 with the addition of 1% Tween® 20 (v/v) for 5 days at 37 °C, 
180 rpm rotation. Sample was analysed on a Superose 12 10/300 column run in 25 mM sodium phosphate buffer 
at pH 8 at room temperature. 
3.7 Fibrils formation during aggregation of GLP-1-Am at pH 7–8 
Samples of GLP-1-Am incubated for 10 days in 25 mM sodium phosphate buffer at pH 8 with 
continuous shaking at 80 rpm at 37 °C was analysed using SEM. From SEM images, it is 
apparent that amyloid fibrils are also formed under these condition (Figure 24), but probably 
not to the same extent as at other pH values, or for GLP-1. SEM images show some other 
aggregate-like species as well, however, it is very difficult to distinguish whether they are 
formed by the peptide or by buffer salts. SEM images of the pure phosphate buffer can be found 
in Appendix B.  
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Figure 24: SEM images of GLP-1-Am aggregates. SEM images of GLP-1-Am after 10 days of incubation in 
25 mM sodium phosphate buffer, pH 8, at 37 °C, with continuous agitation at 80 rpm. Amyloid fibrils are 
highlighted by red arrows. Images A and B are both of the same sample but have different magnifications. 
3.8 Conclusions on the aggregation of GLP-1-Am at pH values 
between 7 and 8 
GLP-1-Am shows a very slow fibrillation when incubated in 25 mM sodium phosphate buffer 
in the pH range of 7–8. The ThT fluorescence increases approximately linearly over the long 
lag phase. There is no rapid increase nor a growth phase observed that would indicate a fast 
elongation combined with a secondary nucleation phase. After 48 hours, small soluble 
oligomers were detected in the incubated samples. The amount of the oligomers gradually 
increased until all monomer was depleted. Based on the size-exclusion calibration curve, the 
size of the oligomers was determined to be in the range from 6.7 to 13 kDa corresponding to 
peptide dimer to tetramers. These small oligomers show a remarkable stability with respect to 
time and they are resistant to heat, sonication and addition of 20% isopropanol. Nevertheless, 
they probably slowly denature when incubated in 40% acetonitrile and during SDS-PAGE 
electrophoresis they denature completely. The structure of these small oligomeric species is 
highly disordered. SEM images of the partially aggregated GLP-1-Am samples showed that 
amyloid fibrils are present to some extent in addition to the oligomers. GLP-1-Am is also prone 
to form soluble oligomeric species when incubated with 1% non-ionic detergent Tween® 20 
(v/v) in 25 mM sodium phosphate buffer at pH 8.  
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Chapter 4  
GLP-1-Am aggregation above pH 8 
 
In this Chapter the aggregation behaviour of GLP-1-Am in solution above pH 8 is investigated. 
All experiments in this Chapter were performed in 25 mM Tris buffer at pH 8.2 or 8.5 (as 
specified further in the text).  
4.1 Large variance in aggregation kinetics 
ThT aggregation assays of GLP-1-Am above pH 8 show large variation in kinetic parameters 
(lag times, k, A) and thus poor reproducibility between equivalent measurements. It can be 
estimated (Figure 25 and 26) that lag times are generally longer than 60 hours and that the 
aggregation profile is, at least at pH 8.5, sigmoidal, as shown for 75 µM GLP-1-Am at pH 8.5 
and 8.2 (Figure 25). This is the greatest difference relative to the aggregation at pH 7 to 8 where 
the aggregation profiles are approximately linear over the same timescales measured. At pH 
8.2, other peptide concentrations (150 µM, 125 µM, 50 µM, 25 µM) showed similar variation 
and lag times longer than 60 hours. Surprisingly, for high peptide concentrations (150 µM and 
125 µM), often no fibrillation was observed over the time course studied (Figure 26). 
 
Figure 25: Irregularity and high variance in ThT aggregation profiles of GLP-1-Am at pH > 8. GLP-1-Am 
at 75 µM concentration at pH 8.2 in 25 mM Tris buffer in a triplicate (blue lines), pH 8.5 in 25 mM Tris buffer in 
triplicate (red lines). All samples were incubated in the same plate. 
Figure 25 illustrates how the slope of the elongation and growth phase is steeper at pH 8.5 than 
at pH 8.2, where the increase in the fluorescence signal in the same region is more gradual and 
closer to aggregation behaviour observed in phosphate buffer between pH 7 and 8 (Figure 11). 
The steep increase in fluorescence in the elongation and growth phase is characteristic of 
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secondary nucleation processes that work as autocatalytic feedback loops.99 The different slope 
of the aggregation curve in the elongation and growth phase at pH 8.2 and 8.5 may be caused 
by the extent of the secondary nucleation processes (secondary surface-catalysed nucleation 
and fragmentation) or even by the absence of those secondary processes at pH 8 in phosphate 
buffer (Chapter 3). Nevertheless, one must take into an account the possible buffer effects of 
Tris versus phosphate buffer. For example, data in Appendix A, Figure A2 show a higher rate 
of fibrillation when GLP-1-Am was incubated in Tris buffer compared to the incubation in 
sodium phosphate buffer (both at pH 7.5). The observed decrease in fluorescence in the plateau 
phase at pH 8.5 (Figure 25) is most probably caused by ThT degradation at high pH.122  
 
Figure 26: ThT aggregation profiles over a range of GLP-1-Am concentrations at pH 8.2. Samples were 
incubated at 37 °C in 25 mM Tris buffer at pH 8.2. Runs in triplicate are shown. 
4.2 Oligomer formation 
The samples were incubated at 37 °C and analysed by SEC (Superose 12 10/300) at 25 °C, 
always in the appropriate version of the Tris buffer. After 24 hours (and longer) of incubation 
at 37 °C, soluble oligomeric species were detected (Figure 27). The elution volumes of these 
oligomeric species significantly differed from the elution volumes of the oligomers detected in 
25 mM sodium phosphate buffer with pH values between 7 and 8. In 25 mM Tris, pH 8.2, the 
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elution volumes of the oligomers were 12.2 mL (larger peak) and 14.1 mL (smaller peak), the 
elution volume of the monomeric peptide was 16.4 mL (Figure 27A). At pH 8.5, the elution 
volumes of the detected oligomers were 11.2 mL (larger peak), 11.8 mL and 13.0 mL (smaller 
peaks), the elution volume of the monomeric peptide was 15.5 mL (Figure 27B). 
However, when the same samples (incubated at pH 8.2 or 8.5) were injected on a column using 
25 mM sodium phosphate buffer with pH 8, as a mobile phase, the same elution profile as for 
the samples incubated at pH 8 sodium phosphate buffer (Chapter 3) was obtained (Figure 12 
and 27). Moreover, in Tris buffer, the elution volume of the monomeric peptide is shifted as 
well. The constant shift in elution volumes (by about 1 mL) of all detected species is apparent 
even between pH 8.2 and pH 8.5 (both in Tris buffer). In this case, it is very probable that the 
detected species are of the same character. In addition, when these oligomers were run on on 
NativePAGE (non-denaturing electrophoresis), they were not resolved since they most 
probably run below the resolving range of 15 kDa.  From these findings it can be assumed that 
the species formed at pH 8.2 and 8.5 in Tris buffer and those formed in phosphate buffer at pH 
7–8 are likely to have the same size and that the difference in elution volumes is due to the 
elution buffer properties (e.g. the pH and ionic strength of the solution). Indeed, the ionic 
strength of 25 mM Tris (pH 8.5 and 8.2) and 25 mM sodium phosphate buffer (pH 8) differs 
greatly, which may play a role in the observed shift in elution volumes.123 
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Figure 27: Shift in elution profiles of monomer and oligomers in different buffers. Same samples analysed on 
a Superose 12 10/300 in 25 mM Tris buffer at pH 8.2 (A, blue line), in 25 mM sodium phosphate buffer at pH 8 
(red line), in Tris buffer at pH 8.5 (B, blue line), and in 25 mM sodium phosphate buffer at pH 8 (red line). The 
observed constant shift in elution volumes is believed to be due to a change in the ionic strength of the elution 
buffer. Incubation of samples was performed at 37 °C in Tris buffer and SEC analysis at 25 °C, always either in 
Tris buffer or in phosphate buffer, always at the appropriate pH. 
4.3 Stability of oligomers formed at pH values above 8 
The oligomeric peak with the elution volume of 11.2 mL (in 25 mM Tris, pH 8.5) was separated 
using SEC and subsequently the stability with respect to time and 30% ACN was tested and 
analysed by SEC (Figure 28). When the separated oligomeric fraction was incubated with 30% 
ACN for approximately 3 hours, the oligomer was partly denatured, presumably, to monomer. 
However, after this, new peaks with higher elution volumes than that of the monomer were 
detected, Figure 28. The new species may be either fragments of GLP-1-Am resulting from 
peptide degradation or differently folded monomers. Similarly to the oligomers formed in 
25 mM sodium phosphate buffer at pH 8, the oligomers isolated in Tris buffer at higher pH 
values show remarkable stability with respect to time (Figure 28). 
-1
0
1
2
3
4
5
5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21
A
2
8
0
 [
m
A
U
]
Volume [mL]
25 mM Tris 
buffer, pH 8.5
-1
1
3
5
7
9
11
13
15
5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21
A
2
8
0
 [
m
A
U
]
-1
1
3
5
7
9
11
5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21
25 mM phosphate 
buffer, pH 8.0
-1
1
3
5
7
9
11
13
15
17
19
5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21
25 mM phosphate 
buffer, pH 8.0
Volume [mL]
B
25 mM Tris 
buffer, pH 8.2
Chapter 4  
GLP-1-Am aggregation above pH 8 
43 
 
 
Figure 28: Stability of the oligomers formed in 25 mM Tris buffer at pH 8.5. Stability of the oligomer formed 
in 25 mM Tris buffer at pH 8.5. (A) The oligomer shows good stability with respect to time and can be partly 
denatured when incubated with 30% acetonitrile for approximately 3 hours. For ACN stability experiment, the 
volume of the injected sample was two times bigger (red line) than in previous injections (blue line, green line). 
(B) The retention volumes of the pure oligomer and of the monomer are shown for comparison. 
4.4 Characterization of oligomers formed at pH 8.5 
The structure of the oligomers was investigated using CD in the far- and near-UV range, and 
using intrinsic tryptophan fluorescence spectroscopy. The far-UV CD spectrum of the 
oligomers isolated using SEC (Figure 29A) shows only a broad minimum at 200 nm 
corresponding to the disordered structure. The spike (marked with *) at approximately 203 nm 
(blue line) is due to noise from the Tris buffer at this wavelength. There is no observable signal 
in the near-UV CD spectrum of oligomers in contrast to that of fibrils formed under these 
conditions, which show two positive bands at approximately 286 and 292 nm (Figure 29B, D). 
In the latter case, this signal comes most probably from the tryptophan residue which is rigidly 
fixed in the structure of fibrils. It is worth noting that the sign of the signal can reveal some 
information about the morphology of the fibrils (at least in the surroundings of tryptophan 
residue) when combined with molecular modelling.114 Under different conditions a negative 
signal was observed at the same wavelengths as the positive signal mentioned previously 
(Appendix C). The far-UV CD spectrum of mature fibrils formed at pH 8.5 (Figure 29C) 
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shows subtle differences when compared to the fibrils formed at pH 8 (Chapter 3, Figure 
19D). Nevertheless, the characteristic β-sheet structural motif can be still observed. 
 
Figure 29: Far-UV and near-UV CD spectra of oligomers and fibrils incubated in 25 mM Tris buffer, 
pH 8.5. Far-UV CD spectrum of an isolated oligomer (A), near-UV CD spectrum of an isolated oligomer (B), far-
UV CD spectrum of fibrils (C), near-UV CD spectrum of fibrils (D). Samples were incubated at 37 °C with 
continuous shaking at 180 rpm and measured at 25 °C. Intensity left in original millidegree units due to the 
difficulties in concentration determination of fibrils and oligomers. 
Trends identical to those observed at pH 8 are also apparent in the tryptophan fluorescence 
emission spectra measured at pH 8.5 (Figure 30). The structure of the monomer does not 
significantly differ between pH 8 and 8.5 as can be seen from i) the value of λmax  (Figure 30 
and Chapter 3, Figure 21) and ii) the CD spectra of freshly prepared samples that were 
previously measured in our group.13 The largest blue shift of λmax to 344 nm can be seen for 
fibrillated GLP-1-Am as opposed to the λmax of oligomers, which is shifted to 361 nm. This 
again indicates a largely unfolded structure of oligomers, which is in agreement with the results 
obtained for oligomers at pH 8 (Chapter 3, Figure 21).  
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Figure 30: Emission maxima (λmax) of the intrinsic tryptophan fluorescence at pH 8.5 in 25 mM Tris buffer. 
The lowest λmax was observed for the folded structure of GLP-1-Am amyloid fibrils (green line) and the highest 
value for the largely unstructured oligomers (red line). 
4.5 Conclusions on GLP-1-Am aggregation above pH 8 
At pH values above 8, slow fibrillation with high variation in many aggregation parameters was 
observed. Under these conditions, aggregation lag times are generally longer than 60 hours and 
then fibrillation occurs. During the lag and elongation phase, formation of small soluble 
oligomers was detected. The oligomers are formed to a greater extent than at pH values from 7 
to 8. This could explain the significant variance in the aggregation kinetics. The structural 
properties of oligomers formed at pH 8.5 in 25 mM Tris buffer are identical to the oligomers 
formed at pH values from 7 to 8 (Chapter 3).  
  
100
150
200
250
300
350
400
450
500
550
600
320 330 340 350 360 370 380
Fl
u
o
re
sc
en
ce
 in
te
n
si
ty
 [
a.
u
.]
Wavelength [nm]
monomer
oligomers
fibrils
353 nm
361 nm
344 nm
Chapter 5 
Discussion 
46 
 
Chapter 5 
Discussion 
 
This Discussion analyses and summarises results described in Chapter 3 and Chapter 4.  
5.1 GLP-1 and GLP-1-Am show a minimum in aggregation 
propensity around their pI 
GLP-1 aggregates over a wide range of pH values. However, the kinetic parameters associated 
with the aggregation reaction are highly pH dependent.12 The same is true for the C-terminally 
amidated analogue of GLP-1, GLP-1-Am.13  
Here, the aggregation of GLP-1-Am has been investigated in further detail, with the objective 
of detecting and characterising oligomeric species formed during the fibrillation. The lowest 
rate of GLP-1-Am fibrillation was observed between pH 7 and 8 in 25 mM sodium phosphate 
buffer. With the increasing value of pH the propensity to fibrillation increases again as shown 
in Figure 31. Nevertheless, the lag time under these conditions remains very long, about 
60 hours or more. Another interesting difference is the change of the shape of the ThT 
aggregation curves even though the lag times did not significantly differ between different pH 
values. Whereas at pH 8, there is a rather gradual increase in fluorescence over the time scale 
of the measurement, at pH 8.5 a sigmoidal shape of the aggregation curve, with steep increase 
in fluorescence in the elongation and growth phase, was observed. At pH 8.2, the ThT curve 
shape is intermediate between those at pH 8 and 8.5.  
The steep increase in fluorescence is generally due to secondary processes such as 
surface-catalysed secondary nucleation or fragmentation that work as autocatalytic loops.99 A 
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Figure 31: ThT aggregation profiles summary. ThT aggregation curves of GLP-1 and GLP-1-Am at 85 µM 
and 75 µM concentration at pH 8 (yellow and green), 8.2 (blue) and 8.5 (red) (A). Detail of GLP-1-Am 
aggregation (B). 
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shape of the aggregation curves different to sigmoidal may result from a different prevalence 
of these secondary processes or might even suggest a more complex aggregation pathway. 
However, it might also be the case that the aggregation propensity, especially at pH 8, is simply 
too low for the elongation and growth phases to be observed over the timescale of the 
experiment. It is not recommended to use very long incubation times (i.e. longer than one week) 
as this can be associated with many complications, e.g. peptide degradation, evaporation or 
possible bacterial contamination, that make it very challenging to study aggregation over time 
periods of this length.  
One can also observe (Figure 31) that the maximal fluorescence amplitude at similar peptide 
concentrations and the same fluorescence gain is significantly lower for GLP-1-Am compared 
to the GLP-1, even when the stable plateau was reached for both peptides (and all monomeric 
peptide was depleted). Also, the lower fluorescence of the plateau, the longer the aggregation 
takes (Figure 31B).This suggests either lower binding of ThT to the GLP-1-Am fibrils at 
neutral and basic pH, for example due to the different morphology of fibrils, or a possible 
difference in the structure of bound ThT that affects its fluorescence, or the presence of a large 
amount of aggregates of a different type that do not bind ThT. Large clusters were apparent on 
the SEM image at pH 8 (Chapter 3, Figure 24), but it was difficult to distinguish whether they 
are peptide or whether they consist of salts from the buffer. SEM images of pure buffer can be 
found in Appendix B. It is also worth noting that at acidic pH the fluorescence amplitudes in 
the plateau phase in ThT assays are comparable for GLP-1-Am and GLP-1 at the same 
concentration.13  
Therefore, we hypothesise that there may be a different aggregation process competing with 
the fibrillation process. This was already suggested for the unusual aggregation behaviour of 
GLP-1 at pH 7.5, where the lag time increases with the increasing peptide concentration, which 
is opposite to the usually observed trend in fibrillation processes following the nucleation-
polymerization mechanism.12 This difference was attributed to the formation of off-pathway 
oligomeric species together with a slow, unimolecular step of monomer conversion to a 
different monomeric form that forms on-pathway oligomers and eventually fibrils.12 Similar 
types of off-pathway behaviour have been already reported for other proteins, e.g. for ribosomal 
protein S6124 or immunoglobulin light chain where the decrease in fibrillation propensity with 
the increasing concentration was explained by dimer formation.125 At pH 6.4, liraglutide 
(lipidated form of GLP-1) also shows more rapid fibrillation as the concentration decreases.26 
The presence of off-pathway species in the aggregation of both GLP-1 and GLP-1-Am is 
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consistent with the finding that at pH 8.2 high concentrations of GLP-1-Am did not show any 
or only a very slow rate of aggregation (Chapter 4, Figure 26). 
One should also take into account that for pH 8, the 25 mM sodium phosphate buffer was used, 
whereas for pH 8.2 and 8.5 the 25 mM Tris buffer was used. Not only it is possible that the 
buffer itself leads to (de)stabilization of different species,44–46 but the ionic strength of the 
buffers also differs greatly. For the 25 mM sodium phosphate buffer at pH 8 the ionic strength 
is 71 mM while for the 25 mM Tris buffer it is only 7 mM at pH 8.2 (at 37 °C) and 4 mM at pH 
8.5 (at 37 °C). In other systems, it was shown that ionic strength can also significantly alter the 
aggregation behaviour.27,28 A possible solution of this problem can be modulation of the ionic 
strength by addition of sodium chloride to keep the ionic strength constant at different values 
of pH. On the other hand, in this approach, the influence of the chloride anion (the Hofmeister 
effect) may appear as well.54,58 Previous studies on GLP-1 conducted in our group showed that 
there is only a slight effect of the ionic strength on GLP-1 aggregation at pH 3.5 (when ionic 
strength was altered by addition of NaCl), more significant changes were observed at pH 8.2 
when samples were incubated with 1% Tween® 80 in different concentrations of NaCl.126 
Studying aggregation behaviour of GLP-1-Am at higher pH values than 8.5 may provide a 
better insight into its aggregation mechanism, however, at very basic pH values a higher 
propensity of peptides and proteins to deamidation has been observed,24 which would largely 
complicate the description of the aggregation process by introducing multiple chemically 
different monomeric or oligomeric peptide species. Moreover, the rate of ThT hydroxylation 
(degradation) is significantly higher at high pH, which complicates the interpretation of ThT 
kinetic curves.122 Therefore, studies at pH > 8.5 were not undertaken. 
Whereas most peptides are most prone to aggregation close to their isoelectric point,40,42 both 
GLP-1 and its amide show an aggregation minimum around their pI values as was shown here 
and in previous studies conducted by our group.13 For GLP-1, the pI was measured to be 5.9 
while GLP-1-Am has a pI around 6.8. The main difference between the two is that GLP-1-Am 
has a much broader minimum in aggregation propensity around its isoelectric point.13 The 
aggregation of GLP-1-Am at neutral basic pH (i.e. 7–8.5) is much slower than at acidic pH 
(3.5–5.5)13. Nevertheless, even under these conditions GLP-1-Am eventually forms amyloid 
fibrils as was shown in this Thesis. 
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5.2 GLP-1-Am forms small soluble oligomers at pH from 7 to 8.5 
At all studied pH values (from 7 to 8.5), small soluble oligomers were detected during the 
aggregation reaction. When analysed on an SEC column in the same phosphate elution buffer, 
the oligomeric species had the same elution volumes regardless of the incubation buffer (Tris 
versus phosphate buffer, Chapter 3, Figure 12 and Chapter 4, Figure 27). Therefore, it can 
be assumed that the oligomeric species formed over the pH range 7–8.5 are of the same size.  
However, samples incubated in Tris buffer (25 mM at pH 8.2 or 8.5) which were subsequently 
analysed on SEC using the a Tris buffer at the same pH (at the analysis temperature), a large 
shift in elution volumes (Figure 27) of both the monomer and the oligomeric species was 
observed compared with the elution in 25 mM phosphate buffer at pH 8. A similar shift was 
previously observed when these buffers were used for the SEC analysis of GLP-1.12 It is 
important to note the different ionic strength of the elution buffers. For the phosphate buffer 
(25 mM at pH 8) the ionic strength was 71 mM whereas for the Tris buffer it was only 11 mM 
(pH 8.2, at 25 °C) and 7 mM (pH 8.5 at 25 °C). For other proteins analysed on a Superose 12 
SEC column, it has been shown that the ionic strength significantly alters the elution profile.123 
A Tris buffer of such a low ionic strength (11 mM or 7 mM) is not ideal for elution since the 
possible electrostatic interactions between peptide molecules and the column matrix are not 
suppressed. To ensure ideal elution conditions, a weak salting-out electrolyte, such as sodium 
chloride, should be added to the buffer. Superose 12 has a residual negative charge and for pH 
values above the pI (of the eluted peptide) the peptide and the column matrix have the same 
charge. It leads to a repulsive electrostatic interaction and earlier elution (so called ion-
exclusion effect).123 
During the incubation of GLP-1 and GLP-1-Am in 25 mM sodium phosphate buffer at pH 8, 
only GLP-1-Am formed small soluble oligomers. Both GLP-1 and GLP-1-Am formed large 
insoluble aggregates (presumably fibrils) under these conditions. In the GLP-1 SEC, elution 
profiles, only a depletion of monomer was observed without detecting any other soluble species 
formed during the aggregation reaction. 
These observations suggest that either GLP-1 is less prone to oligomerization or that the GLP-1 
oligomers are less stable and therefore not detectable by SEC. Amidation of the C-terminus 
may stabilise the oligomeric structure by reducing unfavourable electrostatic interactions in the 
oligomer. The net charge of GLP-1-Am is approximately 0 at pH 8, whereas the net charge of 
GLP-1 is -1. The plot illustrating dependence of the net charge of GLP-1 and GLP-1-Am on 
pH with highlighted ionizable residues can be found in Appendix D. The fact that the 
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fibrillation of GLP-1 proceeds much faster than for GLP-1-Am may also contribute. If the 
monomer is already largely incorporated in the fibril structure (which generally is very stable), 
only a small fraction of monomers is available for oligomerisation. The main, and still unsolved, 
question is whether the oligomerisation observed by SEC is the reason for, or a consequence 
of, the low rate of fibrillation and the rather unusual aggregation profiles (Figure 31) of 
GLP-1-Am at pH 8, 8.2 and 8.5. The formation of the off-pathway oligomers is generally 
considered as the reason of slower aggregation kinetics since they limit the concentration of the 
monomer available for fibril formation. As the monomer gets depleted by fibrillation, off-
pathway oligomers release monomers back into the solution to preserve the equilibrium a thus 
slow down the fibrillation process. Therefore, it is possible that observed oligomers are off-
pathway products. 
A pH-dependent oligomerisation has been reported in a similar system liraglutide, a lipidated 
derivative of GLP-1.26,27 It was found that liraglutide forms either a 7-mer or a 13-mer 
depending on the pH. Liraglutide contains a fatty acid moiety (attached to GLP-1 at lysine  20) 
that was found to noticeably contribute to the stability of the oligomers.127 In the case of 
GLP-1-Am, a simple amidation of the C-terminus may play a similar role as the fatty acid in 
liragluratide, and thus stabilise the oligomer by decreasing electrostatic repulsion. At pH 6.4, 
liraglutide shows a slower fibrillation rate at higher peptide concentrations as opposed to lower 
concentrations.26 This is also in agreement with the behaviour observed for GLP-1-Am at 
pH 8.2 described here (Chapter 4, Figure 26). 
At this pH, GLP-1-Am oligomerization was also observed when the peptide was incubated in 
1% Tween® 20 (in 25 mM sodium phosphate buffer pH 8). The addition of 1% Tween® 20 
slowed the formation of large insoluble aggregates but promoted oligomerisation (Chapter 3, 
Figure 23). This effect has been reported in the literature for other proteins as well.120,121 It was 
suggested that Tween® 20 in a sufficiently large concentration may stabilise some intermediate 
states, and therefore shift the equilibrium of aggregation. It could also function similarly to the 
attached fatty acid in liraglutide, and form micelle-like self-assemblies of peptide monomers. 
The size of the observed oligomers in Tween® 20 (Chapter 3, Figure 23) has not been 
determined since Tween® 20 can alter the elution conditions on the SEC column and 
consequently the elution profile. A proper calibration of a SEC column under these conditions 
would be needed and it is worth reconsidering the choice of the elution buffer, e.g. buffer with 
addition of sodium chloride in order to increase the ionic strength of the eluent and suppress 
possible electrostatic and hydrophobic interactions. 
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5.3 GLP-1-Am oligomers are stable with respect to time, 
temperature and organic solvents 
Over the range of pH values studied in this work (7–8.5) protein oligomers showed a remarkable 
stability with respect to time, temperature, sonication and addition of organic solvents 
(Chapters 3 and 4, Figures 17 and 28). The formation of these small oligomers is quite slow, 
at least at pH 8, where oligomers start to be detectable by SEC after 48 hours (Figure 12). At 
higher pH, the formation of oligomers seems to be faster, however, the exact kinetic parameters 
were not quantified. The oligomerisation rate may also be highly dependent on the peptide 
concentration.  
The remarkably high observed stability suggests either that the oligomers are largely 
thermodynamically favoured or that their formation is irreversible. An irreversible formation 
can occur, for instance, if observed oligomers are chemically modified degradation products or 
covalently linked monomers. However, GLP-1-Am does not have any cysteine residues which 
excludes any linkage via disulphide bridges. Linkage via other residues (e.g. tyrosine) is 
possible but much less probable.128,129 It was also shown that some modifications of the amino 
acids side chains can cause an elution shift on SEC, for example tryptophan oxidation.130 
Therefore, confirmation of the oligomer size by other methods is needed. On the other hand, 
the isolated oligomers were completely denatured during an SDS-PAGE (Figure 18) and a 
partial denaturation occurred during incubation with 30 or 40% acetonitrile in the solution 
(Figure 17 and 28). These results suggest a non-covalent character of the oligomers, but cannot 
fully exclude the possibility of chemical degradation of the peptide. 
Very stable small peptide oligomers have already been reported in the literature. In the case of 
the Aβ peptide, α-synuclein or the islet amyloid polypeptide, formation of small, stable off-
pathway (not forming fibrils) oligomers is promoted by addition of small organic molecules 
(e.g. polyphenols).131,132 Irreversible or almost irreversible dimerization was observed in the Aβ 
peptide incubated under physiological conditions.81,133 In some cases these oligomers were 
resistant to further fibrillation. Stable small oligomers of GLP-1 or GLP-1 analogues have been 
previously reported as well.134,135  
It could be worth testing the stability of the already pre-formed oligomers of GLP-1-Am in 
acidic pH, since at acidic pH GLP-1-Am fibrillation is significantly faster. For liraglutide, the 
equilibrium of the oligomer formation was found to be fully reversible upon changes of pH.27 
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5.4 GLP-1-Am oligomers have disordered structure 
Extracting structural information from the CD spectra of aggregating samples is not 
straightforward, since there are multiple species present, and each contributes to the overall 
spectrum, Figure 19. Moreover, the ratio of the species is changing during the aggregation 
process. To obtain more information, individual chemical species (monomer, oligomers, fibrils) 
were separated from the aggregating mixture and analysed in isolation. 
Oligomeric species, isolated using SEC, formed both in phosphate buffer (pH 7–8) and in Tris 
buffer (pH 8.2 or 8.5) showed the same structural features. Far-UV CD spectra of the oligomeric 
species (Chapter 3 and 4, Figure 19 and 29) show only one broad minimum at around 200 nm 
corresponding to a highly disordered structure. The formation of these oligomers is, therefore, 
accompanied by a partial loss of the secondary structure present in the monomeric peptide. The 
oligomers (similarly to the monomer) do not show any signal in the near-UV CD spectra in 
contrast to the fibrils, which show two positive peaks at approximately 292 and 285 nm, and a 
shoulder at around 280 nm.  
The structural information obtained from CD spectroscopy agrees with the findings from 
intrinsic tryptophan fluorescence emission spectra. Intrinsic tryptophan fluorescence maximum 
of oligomers showed a red-shift from 353 nm to 360–361 nm relative to the monomeric form, 
which indicates a greater exposure of the tryptophan residue to the solvent and thus a more 
unfolded structure. Despite the probably more exposed hydrophobic patches (e.g. tryptophan), 
binding of ANS to the oligomers was not observed. This can be explained by the fact, that these 
oligomers are too small to have a suitable cluster of exposed hydrophobic residues that would 
enable ANS binding. Oligomers also do not bind ThT which is in agreement with the absence 
of any β-sheet structure. This provides a possible explanation of why significantly lower ThT 
fluorescence is observed even in the plateau phase under certain conditions. In these cases, the 
aggregating samples could have contained oligomers (no ThT binding) and fibrils (binding 
ThT) even when they reached the equilibrium and therefore have a lower fluorescence signal 
than samples where all the monomer has converted into fibrils. 
Potential toxicity of oligomers 
The structure and the size of oligomers of amylogenic proteins and peptides detected during 
aggregation is diverse (from disordered to β-sheet) and it is difficult to predict their toxicity.117 
Generally, it has been observed that increased cell toxicity is linked with small hydrophobic 
residues on the surface of the oligomers as this may facilitate undesirable interactions with the 
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lipid bilayers of biological membranes.1,83–85,136 However, these features were observed mainly 
in peptides and proteins responsible for neurodegenerative diseases and extrapolation of these 
findings to the oligomers of GLP-1-Am may not be justified. Nevertheless, the potential 
cytotoxicity of GLP-1-Am oligomers should be assessed.   
5.5 Effect of oligomer formation on fibrillation 
There are many questions arising from these results. How do the oligomers affect the fibrillation 
process? Are they an alternative form of aggregates coexisting with the fibrils or are they 
formed as an intermediate on the fibrillation pathway and subsequently misfold? Are 
oligomerisation and fibrillation dependent on each other? The exact role of these small soluble 
disordered aggregates in fibrillation requires further investigation but the current results give 
us a strong platform from which to investigate this further. 
At pH 8.2 and 8.5, a very low fibrillation rate was observed at higher GLP-1-Am concentrations 
(150 µM, 125 µM), while at lower peptide concentrations fibrillation proceeds faster 
(Figure 25 and 26). Samples of all peptide concentrations contained small soluble oligomers 
(the exact fraction was not quantified). The observed concentration dependence of fibrillation 
is not consistent with a classical nucleation-polymerization mechanism, and, therefore, it is 
likely that oligomers affect fibrillation kinetics and that some of the oligomers formed are 
off-pathway. These findings can be further explored by seeded assays, where pre-formed 
oligomers are used as ‘seeds’, and/or by exact quantification of the fraction of oligomers formed 
for each peptide concentration. 
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6.1 Conclusions 
In this work, the aggregation behaviour of a C-terminally amidated analogue of GLP-1, was 
investigated over the pH range 7–8.5. It was shown that between pH 7 and 8 the aggregation 
rate is low and fibrillation proceeds slowly compared to the non-amidated GLP-1 under the 
same conditions. Above pH 8, aggregation also has long lag times of over 60 hours. Generally, 
at pH above 8, there is a large variation in the kinetic parameters (lag times, k, A), and thus poor 
reproducibility between equivalent measurements. Interestingly, at high peptide concentrations 
(150 µM, 125 µM) samples do not show any significant fibrillation compared to that observed 
at lower concentrations, at least over the time range studied. 
Over the studied pH range (7–8.5),formation of small soluble oligomers of GLP-1-Am was 
detected during aggregation. These oligomers were found to be highly stable with respect to 
time, temperature and sonication. However, they were partly denatured when incubated in 30% 
or 40% acetonitrile and completely denatured during an SDS-PAGE experiment. According to 
analytical SEC, the size of the oligomers formed is in the range from 6.7 kDa to 13 kDa 
corresponding to peptide dimers to tetramers. The structure of the oligomeric species is highly 
disordered. The oligomer formation was accompanied by loss of some of the secondary 
structure present in the monomer, as was shown by multiple probes. Intrinsic tryptophan 
fluorescence emission spectra also show higher exposure of the tryptophan residue to the 
solvent than in the monomeric structure (or in fibrils). This indicates that the structure of the 
oligomers is less tightly packed and that hydrophobic patches are more accessible to the solvent. 
It was also shown that the oligomers do not bind ThT or ANS fluorescent dyes. This is probably 
caused by their small size and the absence of any β-sheet structure. GLP-1-Am oligomers 
usually coexist in an equilibrium with the monomer and fibrils (and possibly other insoluble 
aggregates); however, they do not dissociate or further aggregate when separated from other 
species. Formation of soluble oligomers was also detected when GLP-1-Am samples were 
incubated in phosphate buffer at pH 8 with addition of 1% (v/v) Tween® 20. The size and 
structure of these oligomers appears to be different from those observed in the absence of 
Tween® 20 and will be subject to further research. 
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Elucidation of the exact role of the small soluble species in the fibrillation process certainly 
requires further investigation. The fact that peptide fibrillation is suppressed at higher peptide 
concentrations (at pH 8.2 and 8.5) and that these samples contain a high percentage of oligomers 
and monomers could imply that oligomerisation and fibrillation rates are mutually dependent 
and off-pathway species play a significant role under these conditions. 
6.2 Future work 
First, it is essential to confirm the size of the oligomeric species by a more precise method, e.g. 
native mass spectrometry. It would also be useful to test the oligomeric samples using liquid 
chromatography-mass spectrometry. This could definitely exclude a covalent linkage of the 
oligomers and reveal any potential chemical degradation of the peptide that might precede the 
formation of oligomers. 
It is also worth investigating whether this type of oligomeric species can also form at acidic pH 
and whether a pre-formed oligomer would be stable under such conditions. The aggregation of 
GLP-1-Am has been studied at low pH by ThT assay13, but no SEC analysis to detect or quantify 
oligomers has been performed. Incubation of samples with the addition of a small percentage 
of organic solvent or at a higher temperature can also shift the equilibrium between fibrils and 
oligomers. Therefore, it is also needed to quantify the percentage of oligomers formed under 
different conditions (peptide concentration, ionic strength etc.) in order to better understand 
what role they play in the fibrillation process. Seeded assays with pre-formed oligomers can 
also help with examining the role of oligomers in aggregation or any effect they may have.  
An interesting question arises from the results of this work regarding the remarkable stability 
of the oligomers. What is the reason of the stability of such small oligomers? Can they 
dissociate back into the monomers, or can they form some type of higher-order aggregates? 
What is the role of the amidation in the stabilisation of these oligomers? 
Many studies have highlighted the cytotoxicity of oligomeric species.82–85,136 Since various 
analogues of GLP-1 are used as therapeutic drugs, the threat of potential toxicity should be 
carefully examined. It should also be investigated whether oligomerization does indeed inhibit 
the binding of the peptide to the GLP-1 receptor as is expected. 
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Appendix A 
Aggregation of GLP-1-Am at pH 7 (7.1), 7.5 and 3 
A.1 GLP-1-Am ThT aggregation profiles at pH 3 and 7 
 
Figure A1: GLP-1-Am ThT aggregation profiles at pH 7 and 3. GLP-1-Am samples of 70 and 43 µM 
concentration were incubated at 37 °C in 25 mM sodium phosphate buffer at pH 7 and 3, respectively. Runs were 
done in triplicates. 
A.2 GLP-1-Am ThT aggregation profiles at pH 7.5 
 
Figure A2: GLP-1-Am ThT aggregation profiles in 25 mM Tris (blue) and phosphate buffer (red) at pH 7.5. 
GLP-1-Am samples of 70 µM concentration were incubated at 37 °C in the respective buffer. Runs were done in 
triplicates. 
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A.3 Comparison of GLP-1 and GLP-1-Am ThT aggregation profiles at 
pH 7 
 
Figure A3: GLP-1-Am and GLP-1 ThT aggregation profiles in 25 mM sodium phosphate buffer at pH 7. 
GLP-1-Am samples of 70 µM concentration were incubated at 37 °C in the buffer. Runs were done in triplicates. 
A.4 SEC analysis of GLP-1-Am incubated at pH 7.1 
 
Figure A4: SEC chromatogram of GLP-1-Am at pH 7.1. 40 µM GLP-1-Am after a 3-day incubation in 25 mM 
phosphate buffer, pH 7.1, at 37 °C with continuous shaking at 80 rpm. Run on a Superose 12 10/300 SEC column. 
A.5 SEC analysis of GLP-1-Am incubated at pH 7.5 
 
Figure A5: SEC chromatogram of GLP-1-Am at pH 7.5. 85 µM GLP-1-Am after a 3-day incubation in 25 mM 
phosphate buffer, pH 7.5, at 37 °C with continuous shaking at 80 rpm. Run on a Superdex 75 10/300 SEC column. 
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Appendix B 
SEM images of sodium phosphate buffer 
B.1 SEM images of sodium phosphate buffer 
 
Figure B1: SEM images of sodium phosphate buffer only. Sodium phosphate buffer 25 mM at pH 4, samples 
for SEM prepared analogously to the samples containing peptide. A, B are images of the same sample with 
different magnification. Both images were taken by Frederik Becher.  
A
B
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Appendix C 
Far- and near-UV CD spectra of GLP-1-Am in different 
aggregated states 
C.1 Far- and near-UV CD spectra of GLP-1-Am in different aggregated 
states at pH 3 in citric buffer. 
 
 
Figure: C1: GLP-1-Am fibrils incubated in 25 mM citric buffer at pH 3. Intensities left in original millidegree 
units due to the difficulties in concentration determination of fibrils and potential oligomers. Far-UV CD spectrum 
(left) measured in a 0.1 cm pathlength cuvette, near-UV CD spectrum (right) measured in a 1 cm pathlength 
cuvette. 
C.2 Far- and near-UV CD spectra of GLP-1-Am in different aggregated 
states at pH 3 in sodium phosphate buffer. 
 
 
Figure C2: GLP-1-Am fibrils in 25 mM phosphate buffer at pH 3. Intensities left in original millidegree units 
due to the difficulties in concentration determination of fibrils and potential oligomers. Far-UV CD spectrum (left) 
measured in a 0.01 cm pathlength cuvette, near-UV CD spectrum (right) measured in a 0.2 cm pathlength cuvette.  
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Appendix D 
Ionizable GLP-1-Am residues and a net charge 
 
D.1 Ionizable GLP-1-Am residues and dependence of the net charge of 
GLP-1 and GLP-1-Am on pH value 
 
GLP-1-Am sequence and ionizable residues 
NH2-HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG-CONH2 
Potentially positively charged residues are shown in red; potentially negatively charged 
residues shown in blue. 
 
Figure D1: Dependence of GLP-1 and GLP-1-Am net charge on pH value. Figure taken from (Becher 2019).13 
 
